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Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia diagnosed in
Western countries and is characterized by clonal expansion of B cells. The clinical course
of CLL is diverse and nearly 50% of patients present with chromosomal abnormalities.
Deletion of the short arm on chromosome 17 (del17p) occurs in 5-7% of cases and
presents with the shortest median survival time and often respond poorly to therapy. The
tumor suppressor gene, TP53 is located on this region and it is well established that the
p53 protein regulates multiple functions including: mitochondria biogenesis, response to
DNA damage and redox balance. The objectives of the study were to determine the status
of mitochondria in the mouse TCL1/p53-/- CLL model, role of the enhancer of zeste homolog
2 (EZH2) in drug resistance, and whether use of Auranofin has any therapeutic potential in
CLL. This study determined that TCL1/p53-/- had elevated expression of transcription
factors which regulate mitochondria biogenesis and increase in mitochondria DNA copy
number. Second, TCL1/p53-/- mice had significantly elevated expression of EZH2 protein
relative to TCL1/p53+/+ cells while CLL patients had no distinct pattern of expression. CLL
patients responded to two EZH2 inhibitors with increased Histone 3 Lysine 27
trimethylation, which is contrary to what has been published. Further studies to determine
whether CLL patients carry EZH2 mutations which influence the response to these
inhibitors are needed. Lastly, CLL cells showed significant apoptosis induction upon
treatment with Auranofin despite stromal co-culture protection. Increased expression of
Thioredoxin Reductase 1 (TxnR1), the target of Auranofin was seen in CLL cells upon
stromal co-culture. High apoptotic induction in CLL and minimal cytotoxicity towards stromal
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cells warrant further examination of Auranofin for CLL therapy. The results of this study
identified two relatively unexplored targets, EZH2 and TxnR1, in CLL. Identifying the
mechanism for the contradictory response of the EZH2 inhibitors by CLL cells may reveal a
new prognostic indicator/biomarker. Lastly, Auranofin may prove to be useful in treatment of
CLL patients despite any chromosomal abnormalities or prior treatment, as majority of CLL
cells co-cultured with stromal cells responded to Auranofin with significant apoptosis.
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Chapter 1

Introduction
1.1 Chronic Lymphocytic Leukemia
CLL is the most common form of leukemia and is characterized by clonal B-cell
expansion. Not every patient will experience symptoms but those who do, commonly
experience generalized lymphadenopathy, fatigue and weight loss. Median age of
diagnosis is 65 and affects males twice as often than in females1. According to the revised
National Cancer Institute-sponsored Working Group guidelines for CLL, diagnosis requires
that there be at least 5000 B-cells/μL with cell surface antigen expression of CD5, a T-cell
marker, and B-cell markers: CD19, CD20, CD23 as well as low expression of surface
immunoglobulin, CD79b, and either kappa or lambda immunoglobulin light chains1-3. CLL
cells accumulate not only in the blood but in bone marrow, lymph nodes and spleen. The
clinical course differs for each patient as some may go years before requiring treatment
while others may need to enter immediate treatment. Currently, there is no curative
treatment for CLL, although progress has been made in the last decade in treatment
course. CLL was previously treated with Chlorambucil, an alkylating agent as the main
chemotherapeutic agents for over several decades4. Fludarabine (F-ara-A) was added to
the treatment regimen as it yielded a higher response rate and longer duration of remission
and progression-free survival when used as the first treatment in comparison to
chlorambucil5. This was followed by combining F-ara-A and another alkylating agent,
cyclophosphamide (C). Combination of F-ara-A + C improved the rate of clinical response,
complete remission and progression free survival; however, patients still acquire resistance
to treatment and can experience recurrence 6.
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Currently, a CD20 monoclonal antibody called Rituximab (R), originally developed
for the treatment of lymphomas, has been added to the regimen. The combination of F-araA, cyclophosphamide and Rituximab, designated FCR, has been shown to be effective in
treatment naïve, relapsed and refractory patients6-9. Depending on several factors such as
clinical stage of disease, patient fitness, genetic risk of the leukemia and any prior
treatment, a treatment regimen of FC, FR or FCR may be initiated2. Despite the
improvements seen with FCR for patient naïve and those who have had prior therapy, not
all patients complete response and resistance to this regimen have been documented10, 11.
1.2 Genetic Aberrations Affect CLL Response to Therapy and Survival
Identifying cellular and molecular markers which can aide in determining the
prognosis and best mode of treatment action is constantly being evaluated for CLL. It is well
established that CLL patients who have undergone somatic mutations in the Ig heavy H
chain variable region V genes (IgHV) account for approximately 50% of cases12, 13. Whether
patients have undergone this mutation is of prognostic significance as those who have
undergone IgHV mutation have a relatively indolent disease requiring minimal to no
chemotherapy and longer survival. Oppositely, unmutated IgHV patients tended to respond
poorly to chemotherapy and have shorter survival times12, 14. Differential expression of zetachain associated protein of 70 kDa (ZAP-70) was found between mutated and unmutated
IgHV CLL patients. Upon further comparision between IgHV and ZAP-70, the latter was
found to be an even stronger prognostic indicator than IgHV mutational status15, 16. In
addition to these two markers, cytogenetic studies reveal that nearly 50 percent of patients
have genetic abnormalities; which can influence and predict disease aggressiveness,
response to therapy and overall survival17, 18. Fluorescence in situ hybridization (FISH)
analyses of hundreds of patient samples revealed varying incidences of chromosomal
abnormalities in CLL19. Table 1 indicates in descending incidence the observed genetic
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alterations19. The top four alterations observed were: deletion of the long arm of
chromosome 13 (del13q) was the most prevalent at 55%, followed by deletion of the long
arm of chromosome 11 (del11q) at 18%, chromosome 12 trisomy (16%), and short arm of
chromosome 17 (del17p). The survival times for the patients with the presented
chromosomal abnormalities are presented in ascending hierarchical order in Table 219.
Furthermore, Figure 1 indicates that del17p had the overall shortest median survival time at
32 months followed by del11q (79 months), 12q trisomy (114 months), normal karyotype
(111 months) and del13q (133 months). This indicates that FISH analyses of CLL patients
are an important diagnostic tool and that molecular alterations can significantly affect
patient survival20. Patients with del17p have the worst prognosis and shortest median
survival time and optimal treatment for these patients continues to be a hurdle in the clinic.
A contributing factor to this dismal statistic is that the TP53 tumor suppressor gene is
located in this region. Enumerable research has shown that loss of this gene, or its
mutation, results in altered response to DNA damage, mitochondria function and oxidative
stress.
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Table 1 Incidence of Chromosomal Abnormalities in 325 Patients with Chronic
Lymphocytic Leukemia

From: New England Journal of Medicine, Dohner, H., Stilgenbauer, S., et al., Genomic
Aberrations and Survival in Chronic Lymphocytic Leukemia, 343, 1911. Copyright © (2000)
Massachusetts Medical Society. Reprinted with permission
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Table 2. Hierarchical Model of Chromosomal Abnormalities in Chronic Lymphocytic
Leukemia

From: New England Journal of Medicine, Dohner, H., Stilgenbauer, S., et al., Genomic
Aberrations and Survival in Chronic Lymphocytic Leukemia, 343, 1912. Copyright © (2000)
Massachusetts Medical Society. Reprinted with permission
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Figure 1: Probability of survival from the date of diagnosis among the patients in the
five genetic categories. From: New England Journal of Medicine, Dohner, H.,
Stilgenbauer, S., et al., Genomic Aberrations and Survival in Chronic Lymphocytic
Leukemia, 343, 1913. Copyright © (2000) Massachusetts Medical Society. Reprinted with
permission
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In order to assess the efficacy of new therapeutic agents in CLL as well as analyze
molecular alterations, the importance of patient consent to donate their blood to research is
immeasurable. This is supported by the fact that there is a limitation of well-established CLL
cell lines for research. However, there are several CLL mouse models by which in vivo
studies can be performed. The TCL1 transgenic mouse, along with several others, has
been shown to mimic human CLL disease and is a useful model to perform in vivo studies
of potential therapeutic agents and further understand the biology of this disease21. CLL is
initiated in these mice through driving the expression of TCL1 in immature and mature B
cells through the control of a VH promoter-IgH-Eμ enhancer21. A limitation of the TCL1
transgenic mice is that it retains functional wild-type TP53 and therefore it is difficult to
assess whether new therapeutic agents designed for patients with del17p CLL will see
benefit. To this end, we recently developed the TCL1/p53−/− mice colony by crossing of
TCL1 transgenic with p53−/− mice22. Similar to the TCL1 transgenic mouse,
TCL1/p53−/− mice showed expansion of the CD5+/IgM+ B-cells but with significantly earlier
onset. In addition, TCL1/p53−/− mice showed significantly shorter survival time, and were
more resistant to clinically used DNA damaging agents22. Significantly, these alterations
were comparable to what was observed in patient CLL samples with del17p.
1.3 p53 and Mitochondria Dysfunction in Leukemia
Alterations in metabolism has now been established to be one of the hallmarks in
cancer; a discovery made by Otto Warburg that tumor cells have a preference to glycolysis
instead of aerobic respiration23, 24. Mitochondria are an important organelle as it is the core
for energy generation as well as execution of cell death. p53 has been shown to be actively
involved in mitochondria biogenesis and function either through direct regulation of
mitochondrial genes by transcriptional activation/repression or through influencing other
signaling pathways such as NFκB25, 26. Aerobic respiration (aka oxidative phosphorylation)
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is carried out by five multi-subunit enzymes including: complex I, II, III, IV and F1-FO-ATP
synthase). Loss of p53 has been shown to result in decreased aerobic respiratory capacity
in part through Synthesis of Cytochrome c Oxidase 2 (SCO2) which aids in assembly of
cytochrome c oxidase (COX)27.
Mitochondria are unique in that it possesses its own mitochondrial DNA (mtDNA)
that encode for components of the electron transport chain and replication machinery. P53
was shown to directly interact with the mitochondria polymerase gamma (DNA Pol γ) upon
mtDNA damage; resulting in enhancing the replicative activity of DNA Pol γ. Further, loss of
p53 significantly elevated the susceptibility of mtDNA to damage and thus susceptibility to
mutations28. Fludarabine treated CLL patients had a significant increase in the frequency of
heteroplasmic mitochondrial DNA mutations. Acquisition of these mutations seemed to
associate with elevation in superoxide production29. Relative to normal lymphocytes,
alterations in CLL mitochondria have also been observed. Elevation of free radicals can be
a direct indicator of mitochondria damage; as evidenced by a tetracycline inducible system
for a dominant negative DNA Polymerase Gamma (POLG-dn). Induction of POLG-dn
revealed increased ROS production through the NADPH Oxidase (NOX) system, reduced
mitochondria respiration, and selective sensitivity when inhibited30. Free radicals such as
superoxide are normally produced as a result of electron leakage from the electron
transport chain.
Regulation of mitochondria biogenesis occurs through nuclear encoded transcription
factors including: p53, mitochondria transcription factor A (TFAM), nuclear respiratory
factor-1 (NRF-1), and peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC1α)26, 31-34. Increased number of mitochondria was observed in CLL patients
compared to normal lymphocytes and was found to be related to the level of endogenous
nitric oxide35. Similarly, CLL patients showed greater mRNA expression for mitochondria
biogenesis regulators NRF-1 and TFAM compared to normal lymphocytes. TFAM not only
8

regulates mtDNA copy number and protect its stability, but can also interact directly with
p53; which aids in maintenance of mtDNA36. Studies on skeletal muscle fibers of p53
knockout mice showed reduced mitochondria content and PGC1α protein expression in
gastrocnemius muscle while decreased mitochondria respiration and elevated ROS in
intermyofibrillar mitochondria37.
Increased expression of anti-apoptosis regulators, Bcl-2 and MCL-1, which are
located on the mitochondria have been observed in CLL38, 39. Alterations of mitochondrial
apoptosis regulators were also seen in TCL1/p53−/− mice. Increased expression of antiapoptotic proteins: Mcl-1 and Bcl-XL were elevated in TCL1/p53−/− mice compared to the
p53 wildtype counterpart. Importantly, this pattern was also observed upon immunoblotting
of patient CLL samples with and without del17p. As this was the first report of the
TCL1/p53−/− mouse model, the status of the mitochondria is yet to be investigated.
Determining whether there are any alterations in the mitochondria in TCL1/p53−/− mice has
implications in disease aggressiveness, survival and therapy. Impaired mitochondria
functions in cancer cells result in a preferential switch to glycolysis for energy requirement.
This response to impaired mitochondria results in an increase in glycolytic enzymes which
can be targeted for therapy. Oncogenic K-Ras induction in a tetracycline-inducible system
showed prolonged ROS production resulted in impaired mitochondria function (decreased
mitochondria respiration) and an increase in glycolysis as measured by increased glucose
uptake and lactate production40. Hexokinase II, which catalyzes the first step in glycolysis,
is just one of the numerous glycolytic enzymes that have been reported to be elevated in
tumor cells with impaired mitochondria41. Use of inhibitors such as 3-bromopyruvate to
which covalently modifies hexokinase II was shown to induce apoptosis in leukemic, HL-60
cells41. Therefore, significant impairment of TCL1/p53−/− mitochondria function can be
exploited for therapy.
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1.4 EZH2 and its Role in Cancer
In addition to regulating mitochondria biogenesis and metabolism, p53 is central in
responding to DNA damage. Chemotherapeutic agents used in CLL such as F-Ara-A,
Cyclophosphamide and Chlorambucil function by either directly damaging DNA or inhibiting
a process in DNA synthesis. Upon DNA damage initiated by UV radiation, activated p53
has been shown to transcriptional repression of enhancer of zeste homolog 2 (EZH2), a
protein which is a component of the Polycomb repressive complex 2 (PRC2)42. The PRC2
functions as an epigenetic modifier through its ability to methylate lysine 27 (K27) on
histone 3 (H3)43. Methylation of H3K27 is successive as kinetic studies of the rates of
mono-, di- and tri- methylated residue formation progressively slowed44. The tri-methylated
product of the reaction, H3K27(Me)3, results in chromatin repression. The PRC2 is
composed of several core components including: EZH2, embryonic ectoderm development
(EED), Suppressor of zeste 12 homolog (SUZ12) and RbAp46/48 45. EZH2 contains a SET
domain which is required for the enzymatic activity of the PRC2. Alterations in EZH2 have
been reported in solid tumors (breast, ovarian, prostate) and found to influence tumor
progression, migration and invasion, and drug resistance46-49. EZH2 and the PRC2 regulate
numerous cellular processes based on their repressive functions. Overexpression of EZH2
in mammary epithelial cells resulted in repression (mRNA and protein) of five DNA damage
response components: RAD51L1, RAD51L2, RAD51L3, XRCC2, and XRCC347. These five
Rad51 family members are required in response to perform homologous repair in response
to DNA double strand breaks50.
Elevated expression of EZH2 was observed in cisplatin-resistant A2780/DDP
ovarian cancer cells in comparison to the parental A2780 cells. Knockdown of EZH2
decreased H3K27(Me)3 levels as well as proliferation rates of the A2780/DDP cells. Further
examination of cell cycle distribution revealed a significantly increased percentage of G2/Mphase cells while decreased G0/G1-phase cell; suggesting the reduced proliferation was
10

due to arrest at G2/M49. EZH2 aberrations have also been observed in numerous
hematopoietic malignancies. Overexpression of EZH2 has been detected in Hodgkin’s
disease and non-Hodgkin’s lymphoma51, 52. High co-expression patterns of EZH2 along with
BMI, another PcG protein, in the nucleus of Reed-Sternberg cells were observed for
patients of Hodgkin’s disease; with generally no EZH2 detection of surrounding infiltrating
lymphocytes51. The significance of these observations was the co-expression of EZH2 and
BMI in these cells, as generally, expression of these two proteins are mutually exclusive in
follicular B cells51, 52.
Whether EHZ2 functions as a tumor suppressor or oncogene in leukemia is still not
well understood. Loss of function studies in the MLL-AF9 acute myeloid leukemia (AML)
mouse model where conditional deletions of either EZH2 or EED investigated the role of the
PRC2 complex in disease development and progression53. EZH2-null mice showed
significantly decreased H3K27(Me)3, but showed no survival difference upon
transplantation of cells into lethally irradiated donor mice. However, a difference was
observed upon isolation of EZH2-null leukemic cells from recipient mice and transplanted
into secondary donor mice. When the same experiment was performed on EED-null cells,
mice showed significantly prolonged survival and complete inhibition of H3K27(Me)3 upon
isolation of the leukemic cells following mouse sacrifice53.
Whole genome sequencing analyses of patient samples have also revealed genetic
aberrations of EZH2 and other components of the PRC2. Inactivating mutations were found
for EZH2, EED and SUZ12 in 42% of Early T-cell precursor acute lymphoblastic leukemia
(ETP ALL) cases compared to 11.9% in non-ETP ALL54. Structural modelling suggested the
deletions and sequence mutations observed, majority in the SET domain, would result in
loss of function54. A larger study analyzing various myeloid disorders, two of which were:
myelodysplastic syndrome (MDS) and myelodysplastic-myeloproliferative neoplasms
(MDS/MPN) also revealed inactivating mutations of EZH2. Univariate analyses of patients
11

with and without EZH2 mutations revealed a poorer prognosis for those with the genetic
alterations55. Opposite to loss of function mutations, several studies have shown gain of
function alterations, specifically, tyrosine 641 (Y641), in follicular and diffuse large B-cell
lymphomas (DLBCL)56-58. The location of this mutation is within the SET domain of EZH2
and leads to altering the enzymatic activity of the PRC2. Expression analyses of lymphoma
cell lines with mutant EZH2-Y641 resulted in increased basal H3K27(Me)3 levels compared
to EZH2-wild type cell lines57.
With evidence that alterations in EZH2 are found in both solid and hematologic
malignancies, design of EZH2 inhibitors as a potential therapeutic strategy is rational.
Studies of EZH2 inhibitors have shown therapeutic efficacy in the context of inhibiting
proliferation, inducing apoptosis and inhibiting migration. Use of EI1, which competes with
s-adenosyl methionine (SAM), a cofactor used by EZH2 for methylation, on DLBCL cell
lines showed selectivity towards cell lines with Y641 mutations. DLBCL-Y641 cells showed
proliferation and colony formation inhibition in a dose dependent manner while this was not
observed in EZH2-WT cell lines 59. GSK126, an specific EZH2 inhibitor was also found to
be effective in lymphoma cell lines with Y641 and A677 mutations; leading to decreased
H3K27(Me)3 levels, cell cycle arrest, and reactivation of PRC2 silenced genes. Gene
ontology enrichment analyses revealed common processes were affected among the
responsive cell lines, including: cell cycle regulation, cell death and biological/cellular
processes59. One study which profiled 33 microRNAs in CLL patients based on whether
these microRNAs could influence immunologic subsets, revealed microRNA-101 downregulation was associated with EZH2 over-expression. Observations of EZH2 alterations in
the described lymphomas suggest other hematopoietic malignancies may also have
mutations, overexpression or deletions. As EZH2 has been found to regulate response to
DNA damage, it is still unknown what role(s) EZH2 has in affecting response to therapy in
CLL with and without del17p.
12

1.5 Redox Regulation in the Cell
Free radicals are constantly being produced within the cell as byproducts of
metabolism, fighting off foreign agents and as signaling molecules. As described earlier, the
mitochondria are a primary source of free radical production; specifically O2•−, as a result of
oxidative phosphorylation. Loss of p53, oncogene activation and tumor cells with previous
chemotherapy have been observed to elevate ROS production60-63,64. Antioxidant
mechanisms are in place to ensure proper elimination of these oxidative molecules, as they
have the potential to be damaging to cellular components such as DNA and proteins.
Maintaining homeostasis between oxidative molecules and antioxidants and the processes
which encompass this within a cell is described as ‘redox regulation’ and it is a matter of life
or death for a cell. Another source of O2•− is the plasma membrane NAPDH oxidase (NOX)
which are found to have increased activity for cells which have been oncogenically
transformed30, 40. Other radical reactive oxygen/nitrogenous species (ROS/RNS) include
the hydroxyl anion (HO•), nitric oxide (NOS) and peroxynitrite (OONO-). A non-radical ROS
is H2O2. Elimination of O2•− is performed by superoxide dismutases (SOD) in the reaction of:
O2•− → H2O2 + O2
There are three SODs in humans and are differentially located. SOD1 is located in the
cytoplasm, SOD2 the mitochondria and SOD3 is secreted to the extracellular space65, 66.
Elimination of H2O2 can be performed by catalase (CAT) through the reaction of:
H2O2 → H2O + O2
ROS can also be neutralized by interaction with antioxidant peptides such as glutathione
(GSH) or antioxidant proteins: glutaredoxins (Grx), thioredoxins (Trx), peroxidredoxins
(Prx)67. GSH is the most abundant antioxidant in the cell as concentrations range from 1-
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10mM. GSH functions not only as an antioxidant but also detoxifies xenobiotics, regulates
cell growth, and acts as a store for cysteine. Upon interaction of ROS with GSH:
GSH + Oxidant → GSSG
enzymes such as GPx will utilize NADPH as the reducing equivalent to reduce GSSG →
GSH. In addition, ROS can attack proteins with redox sensitive, thiol containing proteins67.
Oxidized proteins which require to be in a reduced state for function can be returned to this
by GSH, where:
Protein-SSG + GSH → Protein-SH + GSSG
Transcription factors which contain cysteine residues that are sensitive to oxidation include:
p53, NFκB, and Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) (Maillet,2012,Gloire
2006,Lee 2003). In addition, transcriptional response elements for p53, NFκB, and Nrf2 are
found on the promoter regions for genes such as GPX, SOD, and, GCL respectively68-70.
In cases of high oxidative content within a cell, severe GSH depletion can lead to cell death.
Synthesis of GSH occurs through a two-step reaction of the following:
(1) l-glutamate + l-cysteine + ATP → γ-glutamyl-l-cysteine + ADP +Pi
(2) γ-glutamyl-l-cysteine + l-glycine + ATP → GSH + ADP + Pi
In step (1) glutamate cysteine ligase (GCL) ligates l-glutamate to l-cysteine under an ATP
dependent reaction to yield γ-glutamyl-l-cysteine. The final step is catalyzed by GSH
synthase (GS) where γ-glutamyl-l-cysteine is conjugated with l-glycine to yield GSH.

Another important group of antioxidants are the thioredoxins (Trx) and Thioredoxin
reductase (TrxnR) enzymes which help maintain the redox status of proteins. Synonymous
to GSH, ROS-oxidized proteins on their cysteine residues can be reduced back by reduced
Trx (Trx-SH2). Upon oxidation, oxidized Trx (Trx-S2) will be reduced back by TxnR which
uses NADPH as an electron donor (Figure 2). Redox regulation of proteins are important
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as oxidation of sulfhydryl residues on proteins will lead to disulfide formation which can
affect its function. Two Trx forms are found in a mammalian cell: Trx1is localized in the
cytosol while Trx2 is in the mitochondria71. TxnR are also found in the cytosol (TxnR1),
mitochondria (TxnR2) and a testis-specific thioredoxin glutathione reductase (TGR)71.

ROS

ProteinCys(SH2)

Trx-S2

NAPDH
TxnR

ProteinCys(S2)

Trx-SH2

NAPD+

Figure 2 Mechanism of redox regulation of proteins by Thioredoxin and
Thioredoxin Reductase.

Trx can regulate apoptosis as well as activate downstream regulators through
interactions that are redox regulated. Reduction of cysteine residue on by Trx enhanced its
DNA binding activity which allows induction of gene transcription72. The NFκB pathway, in
addition to regulating mitochondria transcription factors as described above, regulates
genes involved in cell survival. Constitutive activation of the NFκB pathway is often seen in
CLL and implicated for promoting cell survival signals73. Trx also regulates apoptosis in
cells through its interactions with apoptosis signal-regulating kinase (ASK-1)74. Reduced Trx
is able to bind with ASK-1 and signal it for degradation; however, oxidation of the residue by
ROS can lead to its dissociation. Activated ASK-1can lead to induction of apoptosis as
ectopic expression of ASK-1 in multiple myeloma cell lines increased apoptosis following
days after transduction of the vectors. Similar results were seen when a tetracyclineinducible system for ASK-1 was introduced into in these cells75.
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1.6 Targeting the Redox System for Cancer Therapy
Targeting the redox system of cancer cells is a therapeutic strategy that is an
ongoing endeavor63, 76. It has been shown in numerous instances that cancer cells have
altered redox states which often result in increased basal levels of ROS. CLL has been
shown to produce abundant ROS as a result of mitochondria metabolism77. Basal O2•−
mean levels were significantly higher in CLLs when compared with peripheral normal
lymphocytes78. CLL cells analyzed from patients who have had prior chemotherapy
produced significantly higher levels of O2•−. Furthermore, measurement of O2•− from a CLL
patient before and after chemotherapy of F-Ara-A and cyclophosphamide showed an
increase in basal O2•− levels29, 35. Several compounds which trigger oxidative stress through
depletion of GSH has been shown to initiate apoptosis in CLL. Use of beta-phenylethyl
isothiocyanate (PEITC), a natural compound found in cruciferous vegetables was shown to
deplete GSH in a time dependent manner and lead to ROS accumulation63. This
mechanism by PEITC was able to take advantage of the intrinsic oxidative stress often
found in cancer cells and lead to selective elimination of oncogenic RAS-transformed cells.
PEITC was also able to induce apoptosis in CLL cells who were resistant to F-Ara-A62. FAra-A sensitive CLL cells had a mean IC50 (μM) of 3.4 ±0.8 and 5.1 ± 0.5 for F-Ara-A and
PEITC, respectively; while F-Ara-A-resistant CLL had an IC50 of 38.6 ± 13.1 and 5.4 ± 0.5
for F-Ara-A and PEITC, respectively62. A study with arsenic trioxide (As2O3) on CLL showed
a dose dependent reduction in viability after 24hr of treatment. Supplementation with CAT,
GSH and n-Acetyl Cysteine (NAC) reduced the cytotoxicity of As2O379. Addition of ascorbic
acid with As2O3 triggered O2•− production as no production was found individually. Ascorbic
acid enhanced the cytotoxicity of As2O3 in both CLL and multiple myeloma cells through
depletion of GSH80. The cytotoxicity of As2O3 has been attributed through its abilities to
inhibit the functions of GPx, TrnxR as well as mitochondrial respiration30, 81, 82. Inhibition of
antioxidant enzymes has been another strategy investigated for cancer therapy. Use of 216

methoxyestrodial (2-ME), an inhibitor of SOD was shown to selectively induce apoptosis in
CLL but not normal lymphocytes83.

1.7 Auranofin
Auranofin (Ridaura) is an FDA approved drug prescribed for the treatment of
rheumatoid arthritis. Rheumatoid arthritis (RA) is an auto-immune disease characterized by
accumulation of cells in the synovial joint which leads to inflammation, joint pain, and
damage. Infiltration of various immune cells (i.e macrophages, T-cells) release both proand anti-inflammatory cytokines, although the former type predominates84. One of the
mechanisms by which Auranofin showed efficacy towards RA is through its cytotoxicity
towards immune cells. However, there is a bimodal effect to this drug as low dose
Auranofin showed prolonging the survival of neutrophils and maintained its ability to
express adhesion molecules85. Higher concentrations of Auranofin was reported to
suppress chemotaxis and shorten the survival of neutrophils through inhibition of Protein
Kinase C enzymatic activity85, 86. Auranofin inhibited IL-6 mediated phosphorylation of STAT
in myeloma cells as well as inhibit NFκB binding activity in a dose dependent manner87.
Apoptosis induction by Auranofin has been shown to be activated by both the extrinsic and
intrinsic pathways as evidenced by cleavage products of caspase-8 (extrinsic) and 9
(intrinsic)87, 88. Auranofin not only has anti-inflammatory properties but with its ability to
conjugate with thiol-containing molecules, it is a redox modifiying drug as well. Auranofin
has been shown to inhibit TxnR activity in Jurkat T-lymphoma, and HL-60 leuekmia cell
lines in a dose-dependent manner89, 90.
As redox alterations are observed in cancers, targeting the redox system is a
rational therapeutic approach. Inhibition of thioredoxin reductase and conjugation to thiolcontaining molecules by Auranofin rationalize the investigation of its and other gold-
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containing phosphine complexes for use as anti-cancer drugs91. Indeed, Auranofin induced
apoptosis in multiple leukemia and solid tumor models in vitro85, 87, 92. While the studies of
Auranofin in CLL were ongoing for this thesis, the first preclinical report of Auranofin’s
efficacy in CLL was published93. The study reported Auranofin to induce endoplasmic
reticulum stress, elevate ROS production and induce apoptosis in CLL93. This is the first
preclinical assessment of Auranofin’s action on CLL. In addition, a Phase I and II study of
Auranofin in CLL has been ongoing under trial: NCT01419691 which can be found at
www.ClinicalTrials.gov.
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1.8 Hypothesis and Specific Aims
The median survival time for CLL patients with del17p is the shortest relative to
other chromosomal abnormalities. Loss of p53 affects multiple parameters including
mitochondria biogenesis and function, apoptosis, response to DNA damage and redox
balance. Development of the TCL1/p53−/− mouse model has provided a unique tool to
further investigate the mechanisms by which del17p CLL patients have an aggressive
disease phenotype. Alterations in apoptotic regulators have been observed in these mice,
yet, the status of the mitochondria in TCL1/p53−/− mice is yet to be determined. Continued
search for novel targets in CLL, not only for those with del17p, are needed. EZH2
alterations: mutations, over-expression, loss of function, has been observed in numerous
types of cancers. Whether EZH2 can serve as a therapeutic target in CLL is unknown. On
the other hand, targeting the redox system of CLL cells has shown promising results.
Auranofin is a known inhibitor for TxnR and has already shown preclinical promise in one
study while the studies for this thesis were ongoing.
I hypothesize that loss of TP53 in Chronic Lymphocytic Leukemia contributes to
drug resistance by altering mitochondrial biogenesis and EZH2 expression but can be
overcome by the redox inhibitor, Auranofin. Specifically, the major goals of this study were
to: determine mitochondria DNA copy number, expression of mitochondria biogenesis
genes, EZH2 status in TCL1/p53−/− mice relative to TCL1/p53+/+ mice as well as between
CLL patients with and without del17p, and test if Auranofin shows any therapeutic potential
for treatment of CLL.
The significance of this study is supported by evidence that loss of p53 results in
alterations affecting the survival and response to therapy in CLL cells. This study aims at
further characterizing the TCL1/p53−/− model, determining the role of EZH2 in CLL which is
yet unknown, and whether use of Auranofin, an FDA approved drug, can be a potential
therapeutic agent. In order to test my hypothesis, my specific aims were:
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Specific Aim 1: Determine the effects of p53 deletion on the mitochondria of TCL1/p53-/CLL cells
Specific Aim 2: Determine if EZH2 promotes disease progression by affecting drug
resistance in TCL1/p53-/- and del17p CLL
Specific Aim 3: Determine if redox inhibition by Auranofin CLL can be a therapeutic
strategy in CLL
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Chapter 2

Materials and Methods

Mice
The generation of TCL1 transgenic and TCL1/p53−/− mice and their maintenance were
described previously 21, 22. All mice were housed in the conventional barrier animal facility at
the University of Texas MD Anderson Cancer Center, and the animal study was carried out
under a research protocol approved by the Institutional Animal Care and Use Committee
(IACUC).

Reagents
Cells were maintained in RPMI-1640 (SigmaAldrich, St. Louis, MO) supplemented with
10% fetal bovine serum (SigmaAldrich, St. Louis, MO), penicillin (100 units/ml) +
streptomycin (100 μg/ml) (P4333, SigmaAldrich, St. Louis, MO) at 37 °C in a humidified 5%
CO2 incubator. Auranofin (A6733, Sigma-Aldrich, St. Louis, MO), Catalase (C1345, SigmaAldrich), N-acetylcysteine (A5099, Sigma-Aldrich), Glutathione (G6013, Sigma-Aldrich),
trans-Platinum(II)diammine dichloride (P1525, Sigma-Aldrich), Chloro[diphenyl(otolyl)phosphine]gold(I) (702749, Sigma-Aldrich), GSK126 (M60071, Xcess Bio, San Diego,
CA), 3-Deazaneplanocin A (11102, Cayman Chemical, Ann Arbor, MI).

Isolation of CLL cells
Primary CLL cells were obtained from the peripheral blood samples of B-CLL patients, who
were diagnosed according to National Cancer Institute criteria (Zweibel, 1998). Prior to
blood collection, informed consent under a research protocol approved by the Institutional
Review Board of MD Anderson Cancer Center were obtained from all patients in
accordance with the Declaration of Helsinki. In all experiments, CLL cells were isolated
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from blood samples by density gradient centrifugation (Huang, 2000) and incubated in
RPMI-1640 medium containing 10% FBS and penicillin (100 U/ml1) + streptomycin
(100 μg/ml) overnight before experiments. Mice splenocytes were isolated as previously
described22. CD19 positive selection of CLL cells were performed using CD19 microbeads
as directed by the manufacturer (130-050-301, Miltenyi Biotech, San Diego, CA).

Assessment of ROS, superoxide and mitochondrial superoxideCellular ROS was
measured by incubating 1x106 cells for 1 hour with either 0.5μM CM-H2DCF-DA (C6827,
Life Technologies, Grand Island, NY) for ROS, 100ng/mL of dihydroethidium (D11347, Life
Technologies, Grand Island, NY) for superoxide or 2.5μM MitoSox Red (M36008, Molecular
Probes, Grand Island, NY) followed by washing and re-suspension in PBS. Cell
fluorescence was measured using a FACSCalibur flow cytometer (Becton Dickinson, San
Jose, CA) equipped with CellQuest Pro software. Flow cytometric data were analyzed using
FlowJo (Tree Star, Ashland, OR).

Real time PCR
RNA was isolated using the RNEasy mini kit (74104, Qiagen, Valencia, CA) with addition of
the DNase clean-up step. cDNA was prepared using 1μg of RNA for reverse transcriptase
using RevertAid First Strand cDNA Synthesis Kit (K1621, Thermo Scientific, Rockford, IL).
mRNA transcript levels were measured by running the reaction mix of cDNA template,
primers and SYBR Green PCR Master Mix (4344463, Applied Biosystems, Grand Island,
NY) on the Viia7 Real-Time PCR System (Life Technologies, Grand Island, NY). Fold
changes were determined by normalizing to β–actin as an internal control and presented as
2-ΔCT. Gene primers can be found in Table 1.
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Table 3 Mouse and Human Primer Sequences
Gene
Mouse
Ms smMito F13597
Ms smMito R13688
Ms HistoneH2A-For-1606
Ms HistoneH2A-Rev-1755
Ms PolgA For-2025
Ms PolgA Rev-2208
Ms NRF1 For- 696
Ms NRF1 Rev- 931
Ms Polrmt For-3051
Ms Polrmt Rev-3295
Ms Tfb1m For- 665
Ms Tfb1m Rev-838
Ms COX1-For
Ms COX1-Rev
Ms PGC1a-For
Ms PGC1a-Rev
Ms TFAM For-590
Ms TFAM Rev-761
Ms CytB-For
Ms CytB-Rev
Ms Twinkle-For
Ms Twinkle-Rev
Ms PolG2-For
Ms PolG2-Rev
Ms ActinB For-16
Ms ActinB Rev-133
Ms EZH2 For-767
Ms EZH2 Rev-895
Ms SUZ12 For-588
Ms SUZ12 Rev-782
Ms EED For-515
Ms EED Rev-643
Human
Hu Twinkle-For1646
Hu Twinkle-Rev1874
Hu GAPDH-For
Hu GAPDH-Rev
Hu ACTB-For-393

Sequence

Reference

CCCAGCTACTACCATCATTCAAGT
GATGGTTTGGGAGATTGGTTGATGT
AGTCTGTTGTCGCTCTTTGG
AGTTGAGTCTTAGTCCTGGG
CCTAAGCTCATGGCACTGAC
TGCTGCTTCCCCTGTTCAAG
TCTCACCCTCCAAACCCAAC
CCCGACCTGTGGAATACTTG
GTCTACAGGAGATGTTCACC
CAGGGAGTGGATGAAGTTG
AAGTTGATGTAGGAGTGGTG
ATGTCTGCCAACTGTAACAG
TGGAGGCTTTGGAAACTGAC
TCCTGCATGGGCT AGATTTC
CGGAAATCATATCCAACCAG
TGAGGACCGCTAGCAAGTTTG
CATTTATGTATCTGAAAGCTTCC
CTCTTCCCAAGACTTCATTTC
AGACAAAGCCACCTTGACCCGAT
ACGATTGCTAGGGCCGCGAT
CATCCCCCGGCCTGG TGTCT
GCCCCG TCGACTGGCTCAAG
TCTGGGAAACTACGGGCGACTCT
TGCTGGGTGTCTGATTGCTGTTC
CACCCGCGAGCACAGCTTCTT
TTTGCACATGCCGGAGCCGTT
TGCCTCCTGAATGTACTCCAA
AGGGATGTAGGAAGCAGTCATAC
CCAGAACAAGCATCAAAAGGAA
GCAGGACTTCCAGGGTAACAG
AAGTTGAGCAGCGACGAGAA
TCCTGGTGCATTTGGCGTAT
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AACTGAACCCCAAACGATGC
CGATTGAGGTCTGGAAAGCG
AAGGTGAAGGTCGGAGTCAAC
GGGGTCATTGATGGCAACAATA
CATGTACGTTGCTATCCAGGC
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94
95
95
95
95
95
95
95
95
95
95
96
96
96
96
95
95
97
97
97
97
97
97

98
98

99

PrimerBank ID: 4501885a1,

Hu ACTB-Rev-642

CTCCTTAATGTCACGCACGAT

Hu NRF1-For-21
Hu NRF1-Rev-288

CCGAGGACACCTCTTACGATG
TACATGAGGCCGTTTCCGTTT

PrimerBank ID : 4501885a1,

Mitochondria DNA copy number
DNA was extracted using the DNeasy Blood & Tissue Kit (69504, Qiagen, Valencia, CA).
100ng of DNA was used to measure mitochondria DNA (mtDNA) copy number using
nuclear DNA (ActinB, Table 3) primers and mitochondrial DNA primers (Ms CytB, Table 3).
The reaction mix of DNA, primers and SYBR Green was run using conditions as previously
described (Venegas, 2012) using a 7900HT Fast Real-time PCR system (Applied
Biosystems, Grand Island, NY).

Western blot analysis
Cell lysates were prepared by addition of ice-cold RIPA buffer (50mM Tris-HCl pH 8,
150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with 1x
cOmplete ULTRA protease inhibitor cocktail (05892970001, Roche, Indianapolis, IN) and 1
x PhosSTOP phosphatase inhibitor cocktail (04906837001, Roche, Indianapolis, IN) on ice
for 30 minutes. Samples were centrifuged at 20,000 x g for 15 minutes and protein
concentration measured with the BCA protein assay (23225, Thermo Scientific, Rockford,
lL). 20μg of protein was separated on a SDS-PAGE gel, transferred onto a nitrocellulose
membrane and analyzed with various antibodies. Antibodies are as follows: Rabbit antiPGC1α (SC-13067, Santa Cruz Biotechnology, Dallas, TX), rabbit anti-TFAM
(ARP31400_P050, Aviva Systems Biology, San Diego, CA), mouse anti-MitoProfile Total
OXPHOS Rodent WB Antibody Cocktail (ab110413, AbCam, Cambridge, MA), mouse antiMitoProfile® Total OXPHOS Human WB Antibody Cocktail (ab110411, AbCam,
Cambridge, MA), mouse anti-β-actin (A5441, SigmaAldrich, St. Louis, MO), mouse anti24
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EZH2 (3147, Cell Signaling, Danvers, MA), rabbit anti-Histone H3 (4499, Cell Signaling),
rabbit anti-Tri methyl Histone 3 (Lys 27) (9733, Cell Signaling), Thioredoxin reductase 1
(ab16840, AbCam, Cambridge, MA)

Measurement of mitochondria respiration
To measure mitochondria oxygen consumption, 7x107 cells were centrifuged at 400xg for 5
minutes at room temperature. The supernatant was removed and cells were resuspended
in 1mL of respiration buffer (25mM mannitol, 75mM sucrose, 10mM KCl, 10mM Tris-HCl,
5mM KH2PO4, pH 7.2). Cells were then loaded into a temperature regulated chamber with a
computer-controlled Clark-type O2 electrode (Oxygraph; Hansatech, Norfolk, UK).

AnnexinV Propidium Iodide apoptosis assay
CLL cells (1×106 cells ml−1) were plated either alone or atop stromal cells (5x104) and
treated with Auranofin for 24h. Following incubation, cells were collected and washed once
with cold 1× Annexin V binding buffer (556454, BD Biosciences, San Jose, CA). Cells were
stained with Annexin V-FITC (cat. no. 556420, BD Biosciences) for 15min, washed once
with binding buffer followed by addition of propidium iodide (287075, Sigma-Aldrich).
Stained cells were washed with room temperature PBS and analyzed immediately by flow
cytometry using a FACSCalibur equipped with CellQuest Pro software.

Glutathione analysis from cell extracts
CLL cells (1×107 cells ml−1) were treated for 3 and 5h with Auranofin, collected and washed
once with PBS. Cells were sonicated with 1xMES buffer prior to deproteination with 10%
metaphosphoric acid (239275, Sigma-Aldrich St. Louis, MO). Precipitated proteins were
removed by centrifugation at 10,000 × g at 4 °C for 15min. The extracts were then
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neutralized and measured for GSH according to the procedures directed by the
manufacturer (703002, Cayman Chemical, Ann Arbor, MI).

NADPH/NADP+ analysis of CLL cells
CLL cells (4×107 cells ml−1) were treated for 1 hour with Auranofin followed by collection and
washing one time with cold PBS. Cell extracts were prepared by addition of either NADP or
NADPH extraction buffer along with lysis buffer and heated for 30min at 60 °C. Samples
were cooled on ice followed by immediate addition of reaction buffer and the opposite
extraction buffer while vortexing. Samples were then centrifuged at 10,000 × g at 4 °C for
10 minutes to clarify the samples. The supernatant was then used to perform the assay as
directed by the manufacturer for the Fluoro NADP™: Fluorescent NADP/NADPH Detection
Kit (NADPH100, Cell Technology, Mountain View, CA).

Auranofin Neutralization Assay
Culture medium was dispensed into a 24 well plate and supplemented with the following:
1mM N-Acetyl Cysteine (A9165, Sigma-Aldrich, St. Louis, MO), 500U Catalase (C1345,
Sigma-Aldrich), 2mM L-Glutathione (G6013, Sigma-Aldrich) or 1mM sodium pyruvate (MT25-000-CI, Fisher Scientific) followed by 1μM Auranofin. The mixture was incubated at
37 °C for 1h prior to addition of CLL cells (1×106 cells ml−1) to each experimental condition.
CLL cells were incubated for 24h followed by analyzing for apoptosis by flow cytometry.

Statistical analysis
All experiments were done in CLL cells from at least three different mice and patient
samples. Statistical significance was analyzed by Student’s t-test, and P values of <0.05
were considered statistically significant. Graph bars and plots were generated using Prizm
software (GraphPad, La Jolla, CA)
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Chapter 3
Mitochondria of TCL1/p53−/− Mice

3.1 Rationale and Background
It is not yet known whether TCL1/p53−/− mice will exhibit mitochondrial alterations
that could help explain its aggressive disease development and reduced survival time. The
aim of this study was to determine the effects of p53 deletion on the mitochondria of
TCL1/p53-/- CLL cells. Given the central role of the mitochondria in regulation and execution
of apoptosis, understanding the biological alterations of CLL mitochondria is valid to
understand how correlative the TCL1/p53−/− mouse model is to CLL with 17p deletion.
Identifying alterations in the mitochondria of TCL1/p53−/− mice may help us better
understand disease aggressiveness upon loss of this tumor suppressor and better
understand this unique mouse model system.
3.2 Results
We first sought to determine if there was an increase in cytosolic or mitochondrial
free radical production. Flow cytometric analysis showed TCL1/p53−/− mice had slightly
elevated mitochondrial superoxide levels but did not reach significance (Fig. 3a). Similarly,
measurement of cellular superoxide levels detected by hydroethidium indicated no
significant difference between the two groups (Fig. 3b).
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Figure 3. Comparison of free radical and mitochondria mass in TCL1/p53+/+ and
TCL1/p53−/− mice. a, Basal levels of cytosolic and mitochondrial superoxide was measured
in the indicated mouse groups by staining of splenocytes with MitoSox Red and b,
hydroethidium and analyzed by FACS, (n=4 per group).

Cytochrome c Oxidase I, a component of complex IV in the respiratory chain was
used to assess any changes in mitochondria-encoded transcripts. A significant decrease in
MT-CO1 transcripts was measured using real-time quantitative PCR (Fig 4a). Nuclear
encoded transcription factors nuclear respiratory factor 1 (NRF-1) and mitochondria
transcription factor A (TFAM) were both elevated in TCL1/p53−/− mice, however, only NRF-1
reached significance (Fig 4b). To further determine which alterations, with respect to
mitochondria biogenesis, occurred, genes involved in mitochondria replication was also
measured. DNA polymerase gamma (POLGA, POLG2) is a mitochondria specific DNA
polymerase. POLGA encodes for the catalytic subunit of the enzyme while POLG2 encodes
for an accessory subunit. Both genes showed an increasing trend in mice without p53 but
did not reach significance. Similarly, POLRMT and TFB1M also showed an increasing trend
without reaching significance. Polymerase (RNA) Mitochondrial (DNA Directed) (POLRMT)
is a mitochondrial DNA-directed RNA polymerase which regulates mitochondria gene
expression. Transcription factor B1, mitochondrial (TFB1M) is a mitochondrial
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methyltransferase that functions to aid the mitochondrial ribosome. No changes were
observed for Twinkle, the mitochondria DNA helicase, as well as for histone 2A (H2A) an
additional housekeeping gene (Fig 4c). To determine if there was an increase in activated
NFκB via p65 phosphorylation, to explain the increase in NRF-1 transcription, Western blot
analysis between the two mouse groups was performed. TCL1/p53−/− mice exhibited
greater basal phosphorylated p65 than the wild-type P53 group (Fig 4d).
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Figure 4. Loss of p53 leads to alterations in mitochondria and nuclear encoded
genes in TCL1/p53−/− mice. a, Real time RT-PCR was used to determine differences in
gene expression of mitochondria and nuclear encoded genes. Mitochondria-encoded gene
expression was compared between mouse groups by measuring COXI (p=0.0128, n=6-7).
b, Comparison of mRNA transcript levels for two nuclear encoded transcriptional regulators
of mitochondria biogenesis, NRF-1 and TFAM are shown for TCL1/p53+/+ and
TCL1/p53−/− mice (NRF1, p=0.0072, n=5-6). c, Genes involved in mitochondria DNA
transcription and replication: POLGA, POLG2, POLRMT, TFB1M, and Twinkle, along with
H2A as a housekeeping gene was measured between the indicated groups (n=5-6). d,
Western blot analysis of phosphorylated p65 between TCL1/p53+/+ and TCL1/p53−/− mice,
β-actin served as internal loading control (n=3 per group).
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Mitochondria DNA copy number is tightly regulated by TFAM. Western blot analysis
revealed increased expression of TFAM in TCL1/p53−/− mice (n=4) (Fig 5a). From this
observation, we sought to determine whether this increase lead to changes in mtDNA copy
number. qPCR using mitochondria and nuclear DNA specific primers was performed on
isolated DNA. Relative to TCL1/p53+/+ mice, a significant increase in mtDNA copy was
observed in TCL1/p53−/− mice (p=0.0229, n=5-7) (Fig 5b). To determine if this increase
resulted in changes in mitochondrial mass, splenocytes were stained with MitoTracker
Green and analyzed by FACS. TCL1/p53−/− mice exhibited a trend of elevated fluorescence
but did not reach significance (p=0.151, n=4) (Fig 5c). Loss of p53 has been shown to
reduce optimal mitochondrial respiration via Synthesis of Cytochrome c Oxidase 2 (SCO2).
SCO2, which is required for assembling the COXII subunit to the COX complex, was shown
to increase mitochondria respiration upon expression in p53−/− HCT116 colon cancer
cells27. To determine if mitochondria respiration is compromised in TCL1/p53−/−, we used a
Clark-type electrode to measure oxygen consumption of isolated cells (Fig 6a). Comparison
of the two mice groups revealed no significant difference in respiration rate (Fig. 6b).

31

Figure 5. Increased TFAM and mitochondria DNA copy number inTCL1/p53−/− mice.
a, TFAM protein expression was shown between TCL1/p53+/+ and TCL1/p53−/− mice by
Western blot analysis (n=4). b, Mitochondria DNA copy number was determined by DNA
isolation from splenocytes and comparing the ratio of mitochondria to nuclear DNA by
qPCR (p=0.0229, n=5-7). c, To determine changes in mitochondrial mass, splenocytes
were stained with MitoTracker Green and analyzed by FACS.TCL1/p53−/− mice exhibited a
trend of elevated fluorescence but did not reach significance (p=0.151, n=4). Student’s t
test was used to determine p values.
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Figure 6. Comparison of mitochondrial respiration between TCL1/p53+/+ and
TCL1/p53−/− mice. a, Basal mitochondria respiration rates were determined using a Clarktype O2 electrode. Equal number of splenocytes were collected per group, re-suspended in
a respiration buffer, and loaded into a temperature-regulated chamber (n=3). b, Respiration
rate was determine by the slope and presented as nmol of O2 /sec.

To determine if alterations seen in the mice would also be found in human CLL
samples, we measured the expression levels of TFAM and PGC1α by Western blot. CLL
patients with 17p deletion showed significantly elevated NRF-1 mRNA transcript levels but
not for TFAM. However, protein expression levels for TFAM and PGC1α were elevated in
17p deleted patients (Fig 7a). When components of the oxidative phosphorylation complex
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were probed, a heterogeneous expression between non-17p deleted and 17p deleted CLL
was observed. All CLL samples expressed relatively comparable levels of complex V (CV)
and complex II (CII). Complex III (CIII) was diminished in CLL #1, 2 and 4, while highest
expression was in CLL #5 and 6. Complex I (CI) also varied in expression with the lowest in
CLL #1 while highest in # 3, 5 and 6 (Fig 7b).

Figure 7. Upregulation of mitochondria biogenesis regulators in CLL patients with
17p deletion. a, Comparison of protein expression levels between non 17p del and 17p del
CLL patients were performed using Western blot analysis. Expression of oxidative pho
phosphorylation chain components (Complex I-V) was determined on 6 CLL samples. CLL
2-4 are non-17p deletion and CLL 1, 5-6 are 17p deleted. b, Mitochondria biogenesis
regulators TFAM and PGC1α expression levels between the indicated subtypes are shown.
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3.3. Discussion
It has been well established that p53 is an important regulator of apoptosis and
metabolism in part, by way of the mitochondria. Alterations in mitochondria function and
mutations in mitochondria DNA have been observed in CLL patients who received
chemotherapy; this intimates a role of mitochondria in disease progression29. In this study,
we aimed to determine if alterations in the mitochondria are present in
TCL1/p53−/− mice and how this could functionally affect the CLL cells.
Our results indicate towards a compensatory response in mitochondrial biogenesis
upon loss of p53. A decrease in mitochondria-encoded COX1 mRNA expression indicates
that transcription of mitochondria encoded genes may be deregulated. A study showed that
with loss of p53, mitochondria respiration was decreased as result of it being a direct
activator for synthesis of cytochrome c oxidase (SCO2)27.
Increase in transcripts for TFAM and NRF-1 support this compensatory response.
Importantly, the increase in TFAM transcript levels also translated to elevated protein
expression and increased mtDNA copy number; which therefore indicates that this was a
functional increase. Studies have shown TFAM elevation can overcome mitochondria
deficiencies induced by physiological damage such as myocardial infarction100. Similarly,
overexpression of NRF-1 was shown to minimize chemically induced mitochondria damage.
Neuronal cells treated with MPTP, which metabolizes to the complex I inhibitor MPP+,
triggered mitochondria damage and elevated ROS production. Transfection of NRF-1 or
TFAM minimized the inhibitory effects of MPP+ by significantly reducing the amount of ROS
production, degree of mitochondrial membrane potential change and intracellular ATP
loss101.
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Despite the loss of p53, it is reasonable to expect to see elevation in NRF-1 and
TFAM. Transcription of TFAM can be directly regulated by NRF-1 and NRF-233 while NRF-1
contain transcriptional response elements for NFkB on its promoter region. Activation of
NFκB by lipopolysaccharide (LPS) induction led to increase in NRF-1 and downstream
targets such as TFAM102. Despite not having LPS induction in the TCL1/p53−/− mice,
aberrant activation of NFκB has been reported in CLL103. The TCL1 oncogene has been
shown to activate NFκB by its interaction with ATM in addition through increased
phosphorylation of IκBα upon treatment with hydroxyurea104, 105.
No significant increase in free radical production, neither mitochondrial nor cytosolic
superoxide was observed in TCL1/p53−/− mice (Fig 3a, b). Two explanations for this lack of
change are possible. Firstly, there was minimal decrease in the oxygen consumption rate of
TCL1/p53−/− mice relative to TCL1/p53+/+ mice (Fig 6b). Superoxide is generated during
oxidative phosphorylation as a consequence of electron leakage from the respiratory
complexes. Dysfunctional mitochondria often result in increased ROS production through
excess leakage of electrons and are often seen in cancers30, 35. Despite not seeing any
changes in the oxygen consumption rate, this does not necessarily exclude the possibility
that defects in the electron transport chain are not present. It could be that any potential
defects are not observable under basal conditions. Future experiments for further metabolic
profiling should be performed using metabolic analyzers which now have the ability to
measure oxygen consumption, ATP turnover as well as maximal respiration capacity under
stressed conditions (i.e. with oxidative phosphorylation inhibitors)106. The second
explanation may be through the increased expression of SOD2; which is responsible for
converting superoxide to hydrogen peroxide. Although transcription for SOD2 is controlled
by p53, it may also be activated by NFκB; therefore, a compensatory mechanism to elevate
SOD2 was already activated to prevent an over-oxidative environment107, 108. Mitochondrial
biogenesis regulators itself can function as free radical sensors. It was hypothesized that
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NRF-1 may be regulated in a redox-dependent matter; given its role in regulating
mitochondria biogenesis and that the mitochondria is the site for where majority of ROS is
produced. Exposure of rat hepatoma cells to the oxidant t-butyl hydroperoxide (t-BOOH)
increased TFAM mRNA expression and mtDNA copy number while NRF-1 translocation to
the nucleus was observed109. Despite loss of p53, basal phosphorylation of p65 in the
TCL1/p53−/− samples supports the possibility of NFκB taking over regulation of the
mitochondria. A study by Mauro et. al showed NFκB’s role in regulating energy metabolism
by balancing the switch between glycolysis and mitochondrial respiration.
3.3 Future Directions
As stated earlier, the TCL1 oncogene was shown to be an activator of NFκB,
however, very little is known whether TCL1 has any influence on the mitochondria. One
study reported TCL1 localized to the mitochondria and helped support mitochondria
membrane potential and interpretation of their result did not look supportive of this
conclusion77, 110. As this was the only measurement regarding the mitochondria performed
in the study, it is yet unknown whether TCL1 can directly affect mitochondria biogenesis.
Therefore, it would be worth transiently silencing TCL1 in TCL1/p53-/- mice and determine if
components of OXPHOS would be altered. Should there be any alterations in mitochondria
function (respiration capacity) or ROS production, it would supportive of TCL1 having
regulatory functions for the mitochondria. In addition, should the increase in NRF-1 and
TFAM be due to compensation by the NFκB pathway, knockdown of TCL1 should decrease
its basal activity. Immunoblotting for phospho-p65 status as well as expression changes of
NRF-1 and TFAM can be performed.
Our study established an important role for mitochondria biogenesis regulators in
the TCL1/p53−/− mouse model. Despite not observing basal respiratory changes or
significant ROS production between TCL1/p53+/+ and TCL1/p53-/- mice, it is possible that
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only when the system is perturbed, that differences may be visible. Use of OXPHOS
inhibitors such as: rotenone (complex I inhibitor), Thenoyl trifluoro acetone (complex II),
antimycin A (complex III), potassium cyanide (complex IV) and oligomycyin (complex V)
can be used to determine if there are functional differences in each of the OXPHOS
components. Further, use of uncoupling agents such as p-trifluoromethoxy carbonyl
cyanide phenyl hydrazone (FCCP) will abolish the proton gradient of the mitochondria and
may reveal whether there are overall differences in maximal respiration capacity between
TCL1/p53+/+ and TCL1/p53-/- mice.
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Chapter 4

Role of EZH2 in CLL
4.1 Background and Rationale
P53 has been shown to directly repress EZH2 transcription upon its activation in
response the topoisomerase inhibitor, doxorubicin42. EZH2 alterations (mutations,
overexpression, and deletions) have been observed in numerous cancers48, 55-58, 111.
Further, use of the EZH2-specific inhibitor GSK126 in diffuse large B-cell lymphoma
(DLBCL) was found to be effective in inhibiting growth of EZH2 mutant xenografts in
mice112. Despite the study showing EZH2 expression can be regulated through activation of
p53, it is yet unknown what role, if any EZH2 has in CLL and whether its expression will be
altered in CLL patients with del17p. It is also yet unknown whether EZH2 inhibitors will have
any potential therapeutic properties for CLL as what has been observed in solid tumors.
The aim of this study was to determine if EZH2 promotes disease progression by
affecting drug resistance in TCL1/p53-/- mice and as well in CLL patient samples with
and without del17p.
4.2 Results
We first sought to determine if there would be any alterations in mRNA expression
of PRC2 components in TCL1 mice splenocytes with and without P53. TCL1/p53−/− mice
showed a significant increase in EZH2 (p=0.013, n=4) and SUZ12 (p=0.0026, n=4)
transcript expression (Fig 8A). However, there was no change in expression for EED. To
see if these transcript changes translate to a protein level, an immunoblot was performed.
In comparison to TCL1/p53+/+ mice, there was a clear increase in expression of EZH2 in
both TCL1 mice with heterozygous and knockout P53 (Fig 8B). SUZ12 expression was
also elevated but seen only in the TCL1/p53−/− mice (Fig 8C).
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Figure 8. Loss of p53 leads to increased expression of EZH2 in TCL1/p53 mice. A,
Real time PCR was performed using RNA extracted from TCL1/p53+/+ and TCL1/p53-/mice splenocytes to measure relative expression of EZH2, EED, and SUZ12. Samples
were run in triplicate with β-actin used as an internal control (n=4 for each group). Data are
expressed as relative expression (2-ΔCt). B, EZH2 expression level was measured by
extracting protein from TCL1/p53+/+ (n=4), TCL1/p53+/- (n=2), and TCL1/p53-/- (n=6) mice
splenocytes. HCT116 p53+/+ cells served as a positive control with β-actin used as a
loading control. C, SUZ12 expression was analyzed by immunoblot on protein extracts from
TCL1/p53+/+ (n=3), TCL1/p53+/- (n=3), and TCL1/p53-/- (n=3) mice splenocytes with βactin used as a loading control.
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Although this pattern of increase in EZH2 was observed in mice, it was pertinent to
determine if this would also be the case in CLL patients. Immunoblot of CLL patient
samples with EZH2 revealed an inconsistent pattern of expression (Fig 9A). FISH results of
CLL samples 6,7, 9-12 classified these as del17p (Fig 9B). Expression was inconsistent as
several del17p patients had from low to non-detectable levels of EZH2. The remaining 6
CLL patients also had a heterozygous expression pattern of EZH2 levels that could not be
explained by their previous treatment history (Fig 9B).

Figure 9. Diverse EZH2 expression level in CLL. A, EZH2 expression from CD19+ CLL
cells were determined by immunoblot with β-actin used as a loading control. B, Table
shows fluorescence in situ hybridization (FISH) results and whether patient were
undergoing treatment during time of sample collection. The CLL sample number matches to
the EZH2 immunoblot in A.
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As there was a differing expression level of EZH2 in CLL patients, we next sought if
inhibition of EZH2 would have any effect on the viability of these cells. A 72hr MTT assay
was performed using 2-fold serial dilutions of GSK126 on several CLL patients (Fig 10A).
The 50% inhibitory concentration (IC50) was the lowest for CLL 1, which also happened to
be del17p at 0.58μM followed by 2.46 and 5.48μM for CLL 2 and 3, respectively (Fig 10B).
To determine if this decrease in viability was through induction of apoptosis, an
AnnexinV/Propidium iodide assay was performed. Minimal apoptosis was induced by
GSK126 at 2μM after 48hr incubation for CLL samples 2-4. An approximately two-fold
increase in apoptosis was observed in CLL 1 (from 20 to 40%) at 2μM GSK126. High dose
GSK126 (10μM) induced significant cell death for CLL 1 and 2 whereas approximately 50%
of both del17p samples remained AnnexinV negative (Fig 10C).
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Figure 10. CLL response to GSK126. A, CLL cells were treated with 2-fold serial dilutions
of GSK126 for 72hr and measured for cell viability by MTT assay. B, 50% Inhibitory
concentrations (IC50) to GSK126 for three CLL patients from A.C, CLL cells were treated
with 2, 5 and 10μM GSK126 for 24hr and assessed for apoptosis by AnnexinV/PI positivity
through flow cytometry.

As the PRC2 complex targets genes which regulate response towards DNA
damage, we next sought whether inhibition of EZH2 would enhance the activity of DNA
damaging agents in CLL. To test this, CLL cells were treated either with GSK126, the
purine analog Fludarabine (F-Ara-A), or the DNA cross-linker oxaliplatin (OXP) as a single
agent or in combination for 24hr. Single agent treatments with 2μM GSK126 exhibited
minimal apoptosis induction in CLL 1, 3 and 4. CLL 2 had high basal level of AnnexinV
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positivity and 2μM GSK126 further elevated this from 35% to 47%. 5μM F-Ara-A also
induced minimal apoptosis in all CLL patient samples while addition of 2μM GSK126 with FAra-A resulted in minimal increase in cell death. 5μM OXP was most effective on CLL 3 by
inducing AnnexinV+ from 18% to 33% apoptosis; however, addition of 2μM GSK126
reduced this to 27%. Single agent OXP treatment resulted in minimal apoptosis in CLL 1
and 2 while adding GSK126 led to a trend of increasing apoptosis (Fig 11A). CLL 4
exhibited minimal response to both single or combination treatments.
The same experiment was performed using 3-deazaneplanocin A (DZNep) to determine if
similar results would be attained while using a different EZH2 inhibitor. Similar to GSK126,
single agent 2μM DZNep was minimally apoptosis inducing to CLL cells while 10μM OXP
lead to significant apoptosis by itself (p=0.0026, n=3). Combining DZNep and OXP also
lead to significant apoptosis relative to the control (p<0.0001, n=3) but not significantly
greater than with OXP alone (Fig 11B). OXP was more effective as a single agent than in
combination with DZNep. DZNep alone induced about 11.8% apoptosis while 25% with
10μM OXP alone. (Fig 11C). Despite having no significant increase between 10μM OXP
alone and in combination with DZNep, the latter treatment resulted in a lower percentage of
viable cells remaining; 48.9% compared to OXP alone at 60.7%.
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Figure 11. Response to combination treatment of GSK126 with F-Ara-A or OXP in
CLL. A, CLL cells were treated with either single agent 2μM GSK126, 5μM F-Ara-A, 5μM
OXP or in combination for 24hr. CLL cells were measured for apoptosis induction by
AnnexinV/PI. B, CLL cells were analyzed for apoptosis following treatment with single agent
2μM DZNep, 5μM OXP or in combination after 24hr. C, Representative dot plot depicting
AnnexinV vs PI of a CLL patient treated with 2μM DZNep, 5μM OXP or in combination after
24hr.
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Treatment of lymphoma cells with GSK126 resulted in decreased H3K273112.
Despite the expression of EZH2, we wanted to ensure that GSK126 was acting on its target
and to see the basal trimethylation status in CLL. To determine these two points, an
immunoblot was performed on CLL cells treated with GSK126 at several doses for 24hr and
probed for H3K27(Me)3. Both CLL samples exhibited basal H3K27(Me)3 and trimethylation
was further increased upon treatment with 0.1, 0.5 and 1μM GSK126 (Fig 12A, B).
Similarly, treatment with the topoisomerase inhibitor Etoposide (Etopo) also resulted in a
dose dependent increase in H3K27(Me)3. To determine if this would also be observed with
DZNep, CLL cells were also treated with 0.5 and 1μM DZNep for 24hr. Similarly, although
not to the same extent, H3K27(Me)3 was increased at 1μM DZNep (Fig 12B).
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Figure 12. Increased H3K27(Me)3 in response to GSK126 and DZNep. A, Protein
extracts of CLL patients treated with 0.1 and 0.5μM GSK126 or 1, 5 and 10μM Etopo for
24hr and immunoblotted for H3K27(Me)3. B, Protein extracts of CLL patients treated with
0.1, 0.5μM, and 1μM GSK126 or 0.5μM, and 1μM DZNep for 24hr and immunoblotted for
H3K27(Me)3. Histone H3 and β-actin served as a control and internal loading control,
respectively.

To understand why we were observing this result, we wanted to ensure that we
were working with the correct compound. To do this, we obtained a second batch of
GSK126, treated the mouse B cell line BaF3 with GSK126 at 2.5, 5 and 10μM for 48hr and
immunoblotted for H3K27(Me)3. Both stocks resulted in near or complete inhibition of
H3K27(Me)3 after 48hr of treatment. This inhibition was not due to an artifact via decrease
in Histone H3 expression as its expression did not change (Fig 13A). To see if this would
also be seen in a human cell line, Daudi cells, a B cell Burkitt’s lymphoma cell line was
treated with 2μM GSK126 for 40hr from stock 1 and 2. Similarly, Daudi cells had a strong
basal H3K27(Me)3 expression level which was depleted to nearly half after treatment (Fig
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13B). When CLL samples were treated with either stocks of GSK126 at 5 and 10μM,
H3K27(Me)3 expression was increased (Fig 13C). To see if this was a time sensitive
response, as the BaF3 and Daudi were treated for over 24hr, CLL cells were also treated
for 24 and 48hr at 5μM from both drug stocks. Opposite to BaF3 and Daudi cells,
H3K27(Me)3 was elevated and maintained even after 48hr of treatment (Fig 13D).

48

Figure 13. Inhibition of H3K27(Me)3 by GSK126 non-CLL cells. A, Mouse B cell BaF3
cells treated with doses of 2.5, 5 and 10μM GSK126 from stock 1 or stock 2 for 48hr and
probed for H3K27(Me)3. B, Burkitt’s lymphoma Daudi cell line treated with 2μM GSK126
from stock 1 and stock 2 for 40hr and probed for H3K27(Me)3. C, Protein extract of a CLL
patient treated with 5 and 10μM GSK126 from stock 1 or stock 2 for 24hr and
immunoblotted for H3K27(Me)3. D, CLL patient treated with 5μM GSK126 from stock 1 or
stock 2 for 24 and 48hr before whole cell protein extraction was performed and
immunoblotted for H3K27(Me)3. Histone H3 and β-actin served as a control and internal
loading control, respectively for all immunoblots.
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The response to GSK126 was consistently observed although the degree to
increase in H3K27(Me)3 varied as there was a significant difference in basal and GSK126induced H3K27(Me)3 signal intensity (Fig 14). Two images with short and long exposure
lengths are presented as CLL 1 required a longer exposure than for CLL 2. CLL 1 had less
basal H3K27(Me)3 than CLL 2 but was still responsive to 5μM GSK126 after 24 and 48hr.
CLL 2 had intense H3K27(Me)3 signal without GSK126 treatment and was further elevated
upon treatment. Increased H3K27(Me)3 was also maintained after 48hr of treatment.

Figure 14 Increased trimethylation is maintained in CLL. A, Two CLL patients were
treated with 5μM GSK126 for 24 and 48hr and immunoblotted for H3K27(Me)3.Two
exposure times are presented to exhibt changes in trimethylation. Histone H3 and β-actin
served as a control and internal loading control, respectively for all immunoblots.

To determine if this increase in H3K27(Me)3 was due to alterations in the expression
of EZH2 itself, we treated cells with GSK126 and probed for changes in EZH2. Dose
dependent treatment of cells with GSK126 revealed an increase in EZH2 at 10μM (Fig
15A). However, because an increase in H3K27(Me)3 was observed even as low as 0.1μM,
this change could be a non-specific response. Further examination with CLL samples
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showed only CLL 4 increased EZH2 expression after 5μM GSK126 after 24hr (Fig 15B).
These results also further support that each CLL patient expressed varying basal levels of
EZH2.

Figure 15. GSK126 does not affect EZH2 expression. A, Protein extracts of a CLL
patient treated with 1, 5 and 10μM GSK126 or 5μM OXP for 24hr and immunoblotted for
EZH2. B, Four CLL patients treated with 5μM GSK126 or 5μM OXP for 24hr and
immunoblotted for EZH2. β-actin served as a loading control for both experiments.

As the PRC2 complex is important for regulation of DNA damage response, we
hypothesized that loss of EZH2 would alter its response towards DNA damage. We also
wanted to know if loss of EZH2, rather than its pharmacological inhibition would alter its
viability. To answer these two questions, BaF3 cells were electroporated with EZH2 siRNA
for 48hr and treated with 5 or 10μM OXP for 24hr. Immunoblot analysis was performed on
electroporated cells to determine the efficiency of transient knockdown. Relative to control
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siRNA, 50nM EZH2 siRNA resulted in nearly complete knockdown of basal expression
levels of EZH2 (Fig 16A). Despite near complete loss of EZH2, there was no further
induction of apoptosis in the DMSO control cells. Further, 5 and 10μM OXP resulted in 60
to 80% AnnexinV positivity, respectively (Fig 16B).

Figure 16. EZH2 knockdown does not affect sensitivity to OXP. A, BaF3 cells were
electroporated with 50nM control or EZH2 siRNA and incubated for 72hr. Protein was
extracted and immunoblotted for EZH2 while β-actin served as a loading control. B, BaF3
cells with EZH2 knockdown were treated with 5μM and 10μM OXP for 24hr and assessed
for apoptosis by AnnexinV/PI flow cytometry assay.
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4.3 Discussion
The aim of this study was to determine if EZH2 promotes disease progression by
affecting drug resistance in TCL1/p53-/- mice.GSK126 was shown to inhibit H3K27(Me)3 in
lymphoma cell lines112. However, our results suggest that EZH2 inhibition is not a feasible
therapeutic strategy; either as a single agent or as an adjuvant to increase sensitivity to
currently used chemotherapeutic agents for CLL. We consistently observed CLL cells
responding to GSK126 and DZNep with increased H3K27(Me)3.This increase was an
unexpected result as prior studies showed both drugs resulted in decreased H3K27(Me)359,
112

. To ensure that what we observed was not due to an artifact, two different stocks of

GSK126 was tested on two cell lines: BaF3 and Daudi cells. Immunoblotting for
H3K27(Me)3 revealed an inhibition upon treatment with GSK126 in both cell lines. These
results indicate that both GSK126 drug stocks possessed the activity as reported and that
what was being observed in the CLL samples was not due to an error in the compound or
its preparation. The increase in H3K27(Me)3 was also maintained after 48hr of treatment
which indicates that it is not an acute stress response to GSK126. It is yet unknown as to
the exact mechanism(s) for the increased methylation. It is possible that alternate signaling
mechanisms may be compensating for the loss of EHZ2. Such was the case where EZH2
knockout embryonic stem cells had residual H3K27(Me)3 which was attributed to EZH1113.
Methyltransferase activity inhibition for GSK126 is indicated to be in the nanomolar
concentrations59. Despite inhibiting cell viability as indicated by the MTT assay, two out of
the three patients would require concentrations that are significantly higher than required to
inhibit the methyltransferase activity. One can infer that the observed inhibition of cell
viability was a result of off target effects. Furthermore, siRNA knockdown of EZH2 in BaF3
cells did not alter basal apoptosis levels nor alter sensitivity towards OXP.
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Addition of EZH2 inhibitors in combination with F-Ara-A or OXP also failed to further
enhance the cytotoxicity of the two chemotherapeutic agents. OXP alone significantly
induced apoptosis but addition of DZNep had no significant effect. F-Ara-A and GSK126
was only minimally beneficial for one CLL patient when in combination. These experiments
were approached with the hypothesis that inhibition of EZH2 will remove the repressive
effect the PRC2 has on genes which regulate DNA damage response. Re-activation of
such genes may be beneficial for CLL chemotherapy as significant DNA damage, to the
point where repair is not sufficient, will lead to initiation of apoptosis. However, the observed
results of minimal increase in drug sensitivity as well as increased H3K27(Me)3 in CLL cells
indicate that these cells are not responding to GSK126 or DZNep as has been previously
reported.
4.4 Future Directions

In order to determine the mechanism by which increased H3K27(Me)3 was
observed upon treatment with EZH2 inhibitors, the following experiments are proposed:
Despite having less trimethylation activity than EZH2, EZH1 expression levels in
samples where significant increase in H3K27(Me)3 is observed upon DZNep/GSk126
treatment should be performed. In addition, methyltransferase activity assays, should be
performed in parallel to determine whether enzymatic activity of EZH2 is really being
inhibited. If EZH1 activity is elevated more-so than EZH2, it is possible that despite GSK126
inhibition, which is primarily selective towards the SET domain within EZH2, will have
continued methylation activity. As stated earlier, EZH1 has been shown to have less
methylation activity in comparison to EZH261. However, this does not explain the results
observed with DZNep, as it is a more general EZH2 inhibitor than GSK126. The primary
target of DZNep is S-adenosyl-L-homocysteine hydrolase which is an enzyme involved in
metabolizing s-adenosylhomocysteine (SAH)106. SAH is important in regulating
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methyltransferase activity as its accumulation will inhibit methylation reactions40,43. Thus,
DZNep is not as specific as GSK126, yet H3K27(Me)3 elevation was still observed in CLL
cells.
Another approach to decipher the reason for what is observed is to perform DNA
sequencing of CLL samples for EZH2. As mutations have frequently been observed within
the SET domain of EZH2 in lymphomas, it is quite possible that similarly, mutations are
observed in CLL66. Although, the mutations would most likely be different as GSK126 was
able to be more effective in lymphoma cells possessing mutant EZH2 than wildtype66.
Limitations of understanding the role of EZH2 is due to the diversity observed in each
patient, heterogeneity of the leukemia population seen even within one patient, and the
constant evolution of tumor cells as the disease progresses or after therapy. Nonetheless,
genomic sequencing would be worthwhile for CLL patients to help find an explanation to
this increased trimethylation.
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Chapter 5

Therapeutic Potential of Auranofin for CLL Therapy
5.1 Background and Rationale
Treatment response in CLL depends on a multitude of factors including genetic
abnormalities. Despite the progress made in treating CLL, there is still not curative therapy
for this disease. Targeting the redox status of CLL by pro-oxidant agents such as PEITC
and 2-ME has been shown to be effective in inducing apoptosis62, 83, 114. Auranofin is an
FDA approved drug used for the treatment of rheumatoid arthritis and functions through
inhibition of the antioxidant, Thioredoxin Reductase (TxnR). The aim of this study was to
determine if Auranofin shows any therapeutic potential for the treatment of CLL.
5.2 Results
Mitochondria of leukemia cells have been found to have elevated ROS levels when
compared to primary normal B cells29, 35. Our lab has previously established a tetracyclineinducible dominant negative DNA Polymerase Gamma cell line30. To test if Auranofin
exhibits any cytotoxicity to cells with dysfunctional mitochondria, an apoptosis assay was
performed. Doxycycline induced Tet-POLGdn cells were induced for four days followed by
48hr treatment with Auranofin. Relative to the non-induced ‘Off’ cells, 1μM Auranofin
reduced the viability from 86.1% to 68.2% in the ‘+Dox’ group compared to 92.5% to 80.4%
in the ‘Off’ (Fig 17A). Further doxycycline induction to a total of 7 days lead to even greater
apoptosis at 1μM Auranofin (Fig 17B).
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Figure 17. Increased sensitivity to Auranofin in cells with dysfunctional
mitochondria. A, Apoptosis induction was compared in Tet-POLGdn cells with and without
doxycycline induction. Tet-POLGdn were induced for 4 days followed by 48hr treatment
with 1μM Auranofin. Apoptosis was measured by AnnexinV/PI assay.Values depict
percentage of cells that were AnnexinV and PI negative. B, Comparison of Tet-POLGdn
Off, 6 and 7 day doxycycline induced cells to 0.5 and1μM Auranofin for 48hr. Graphs
represent the mean of triplicate ± SD. p value was determined by student’s t-test.
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To first determine whether there would be any cytotoxicity of Auranofin to CLL cells,
an MTT assay was performed. CLL cells were treated in two-fold dilutions of Auranofin for
72 hours (Fig 18A). CLL cells had a range in sensitivity, between 0.1 to 2.4μM Auranofin,
for 50% inhibition as depicted in the table (Fig 18B). As Auranofin targets the TxnR
enzyme, we sought to determine if there would be any indication of response to Auranofin
with relation to the expression levels of the protein. Western blot analysis of CLL cells
revealed a heterogeneous pattern of TxnR1 protein expression (Fig 18C).
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Figure 18. Impact of Auranofin on CLL survival. A, CLL cells were treated in
quadruplicates at 2-fold serial dilutions of Auranofin for 72hr and measured for cell viability
by MTT assay. B, 50% Inhibitory concentrations (IC50) values (μM) to Auranofin in CLL
patients (n=5). C, CLL protein extracts were immunoblotted to assess basal TxnR1
expression levels. β-actin serves as a loading control.
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As CLL is described to be a disease of irregular clonal expansion, its pathology is
also identified as having defective apoptosis. The latter is supported by the evidence of
elevated expression of anti-apoptotic proteins such as Bcl2 and Mcl138, 39. Despite showing
responsiveness in the MTT assay, this did not indicate whether Auranofin was able to
trigger cell death in CLL cells. At the same time, we also asked whether Auranofin would be
cytotoxic to a relatively ‘normal’ cell line. To answer these questions, an
AnnexinV/Propidium Iodide assay was performed. CLL cells and immortalized bone marrow
stromal cells (NKTert) were treated for 24 hours and analyzed by flow cytometry. CLL cells
showed over 60% cell death at 0.5μM with no further increase at 1μM. In contrast, NKTert
showed minimal cell death at these same concentrations (Fig 19A). We next sought to
determine if co-culturing the CLL cells with NKTert cells will minimize the apoptotic effect of
Auranofin. Numerous studies have shown that the CLL microenvironment (i.e. bone
marrow, lymph node) affords a protective effect to these cells. CLL cells have been shown
to have increased resistance to chemotherapeutic agents upon stromal co-culture115-117. It
would be important to know if the efficacy of Auranofin would be diminished upon stromal
co-culture support. To determine if this would be the case, CLL cells were seeded atop
NKTert cells at a CLL:NKTert ratio of 20:1. Stromal cells alone increased the viability of CLL
cells from 83.4% to 97%. Interestingly, rather than a decrease in cytotoxicity towards
Auranofin, CLL cells showed greater cell death with co-culture (Fig 19B). Further tests
confirmed significantly increased sensitivity towards 1μM Auranofin upon NKTert co-culture
(p<0.0001, n=23) with CLL samples (Fig 19C).
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Figure 19. Selective sensitivity sensitivity to Auranofin by CLL cells. A, CLL and
NKTert were treated with 0.5 and 1μM Auranofin for 24hr and assessed by AnnexinV/PI
assay for apoptosis induction. B, CLL cells either alone or co-cultured atop NKTert cells
(CLL:NKTert, 20:1 ratio) were treated with1μM Auranofin for 24hr and assessed by
AnnexinV/PI assay. C, Result of total AnnexinV positive CLL cells measured in either
duplicate or triplicates treated with 1μM Auranofin for 24hr. Basal apoptosis was subtracted
from each group to show Auranofin-induced apoptosis (p<0.0001, n=23). Values on dot
plots depict percentage of cells negative for AnnexinV and PI and p value was determined
by student’s t test.
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To determine if the increased sensitivity of CLL cells to Auranofin was due
specifically to the NKTert bone marrow stromal cells, we performed the same experiment
on the lymph node stromal cells HK. In comparison to NKTert cells, HK cells did not afford
as great a protective effect on the control cells; 66.3% on HK compared to 73.6% alone.
There was approximately 54% induction of apoptosis in the CLL alone group at 0.5μM
Auranofin versus 24% with the CLL + HK group. However, at 1μM Auranofin, CLL+HK cells
showed 79% cell death whereas CLL alone showed only 36% death (Fig 20A). Further
tests at 1μM Auranofin between CLL alone and CLL+HK showed significant increase
(p=0.0139, n=4) in AnnexinV positivity after 24 hour treatment (Fig 20B).
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Figure 20. Increased sensitivity of CLL towards Auranofin when co-cultured on HK
stroma. A, CLL cells either alone or co-cultured with HK cells (CLL:HK, 20:1 ratio) were
treated with1μM Auranofin for 24hr and assessed by AnnexinV/PI assay. B, Results of total
AnnexinV positive CLL cells measured in either duplicate or triplicates treated with 1μM
Auranofin for 24hr. Basal apoptosis was subtracted from each group to show Auranofininduced apoptosis (p=0.0139, n=4). Values on dot plots depict percentage of cells negative
for AnnexinV and PI and p value was determined by student’s t test.
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Previous studies have shown CLL have intrinsically higher basal ROS levels and
this may be taken advantage of for selective elimination of leukemic cells35, 62. Given the
importance of TxnR in maintaining redox balance, we sought to determine what redox
alterations Auranofin may be causing in CLL cells. Indeed, a dose dependent elevation of
intracellular ROS, as detected by DCF-dA, was observed upon one hour Auranofin
treatment. ROS increase was observed at 0.5μM (dotted line) with greater elevation at 1μM
(solid black) and slightly further at 2μM (dashed line) when compared to DMSO control
(filled gray) (Fig 21A). Further studies showed a plateau in ROS production after 1μM
Auranofin as there appeared to be nearly the same fluorescence intensity at 2μM (Fig
21B). To see if this elevation of ROS is an acute oxidative burst or prolonged event, CLL
cells were treated at two time points and measured with DCF-dA. Out of four patients, three
showed elevation after one hour of Auranofin treatment but with reduction to near basal
levels by four hours. However, one patient exhibited a delayed elevation in ROS as an
increase was observed only after four hours (Fig 21C). To determine if this acute increase
in ROS could be inhibited, CLLs were co-treated with the antioxidant, N-acetyl cysteine
(NAC). 2mM of NAC was able to prevent/reduce the excess ROS production triggered by
Auranofin in all three patients (Fig 21D). Further, NAC was able to reduce the basal ROS
levels in patient CLL3. Further examination at lower (1mM) and higher (3mM)
concentrations of NAC was able to reduce ROS production relative to Auranofin alone (Fig
22).
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Figure 21. Auranofin triggers ROS production in CLL cells. A, CLL cells were treated
with DMSO (filled gray), 0.5μM (dotted line), 1μM (solid black) and 2μM (dashed line)
Auranofin for 1hr and measured for ROS production by DCF-dA staining. B, CLL cells were
dosed with 1μM and 2μM Auranofin for 1hr and assessed for ROS production by DCF-dA
staining (n=4). C, CLL cells were dosed with 1μM Auranofin and incubated for 1 and 4hr
prior to measuring ROS production with DCF-dA (n=4). D, CLL cells were treated with
DMSO, 2mM NAC, 1μM Auranofin or NAC+ Auranofin for 1hr and measured for ROS
production by DCF-dA. Values on graphs (B-D) represent mean fluorescence intensity.
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To further determine whether there is a dosage effect of NAC to inhibit ROS
produced by Auranofin, a dose study was performed. As expected, Auranofin alone lead to
significant production of ROS in both patients at 1 and 2μM. Using 1mM NAC inhibited over
50% of ROS production in CLL1; with complete inhibition at 2 and 3mM NAC. However,
CLL2 required the 3mM NAC to prevent the production of ROS by Auranofin. Despite
reduction of the degree of Auranofin-induced ROS relative to the no NAC group, ROS was
still induced at 1 and 2mM NAC when compared to its control (Fig 22).
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Figure 22. NAC diminishes Auranofin induced ROS production. CLL cells were dosed
with no NAC, 1mM, 2mM or 3mM NAC in combination with DMSO, 1μM or 2μM Auranofin
for 1hr. Cells were stained with DCF-dA analyzed by flow cytometry. Graph bars represent
mean fluorescence intensity.
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Oxidative balance within a cell can be a life and death situation. Because cells have
various processes by which free radicals can be produced, a competent antioxidant system
must be in place. Glutathione (GSH) is the most abundant antioxidant within a cell and may
even be found in millimolar concentrations118. Depletion of GSH within a cell can trigger
apoptosis and has been found to be a potent and selective mechanism for eliminating CLL
cells62, 117. Because significant ROS was observed by Auranofin, we wanted to determine if
GSH was depleted in CLL cells. CLL cells treated with 1μM Auranofin showed significant
depletion at both three (p=0.031, n=8) and five hours (p=0.0078, n=8) (Fig 23A). We can
also observe that each patient had heterogeneous basal GSH concentrations. GSH and
thioredoxin (Trx) undergo an oxidation and reduction reaction to maintain the redox balance
in the cell. This is performed by their respective oxidoreductase enzymes, Glutathione
Reductase (GR) and TxnR, respectively. In order to carry this reaction out, NADPH is
required as the reducing equivalent. Because Auranofin is known to inhibit TxnR, we
hypothesized that the NADPH/NADP+ ratios would be altered. As expected, treating CLL
cells for one hour with 1μM Auranofin lead to an increase in the NADPH/NADP+ ratio in all
four CLL patients (Fig 23B).
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Figure 23. Auranofin leads to GSH depletion and increased NADPH/NADP ratios. A,
CLL cells were treated with 1μM Auranofin for 3 and 5hr prior to collection and measured
for total GSH concentration (n= 8). B, CLL cells were treated with 1μM Auranofin for 1hr
before extracting for NADPH and NADP+. Bar graphs represent the ratio of
NADPH/NADP+ concentrations.

CLL cells treated with Auranofin showed significant production of ROS after one
hour of treatment. However, it is not known whether stromal co-culture will prevent ROS
production. Previous studies showed that stromal co-culture can decrease basal ROS
levels and elevate GSH levels117. Zhang et al. showed CLL:stromal co-culture significantly
elevated GSH after 72 hours. To determine if GSH levels can be altered at an even shorter
co-culture period, we seeded CLL cells on NKTert cells for the indicated times and
measured for GSH levels. We were able to observe a 151% and 254% elevation in GSH for
CLL1 and CLL2, respectively. After 24 hr co-culture, a 23% and 71.5% increase in GSH for
CLL3 and CLL4, respectively was observed (Fig 24A). Again, these results highlight the
heterogeneity in basal GSH levels between CLL patients as well as the degree to their
response in up-regulating GSH levels upon stromal co-culture. The changes in GSH levels
indicate a change in the redox status upon stromal co-culture and so our next question was
whether this co-culture will alter ROS production induced by Auranofin treatment. CLL cells
were seeded on NKTert cells and treated with 1μM Auranofin for one hour. As observed
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earlier, CLL cells alone produced significant amounts of ROS upon Auranofin treatment
(p=0.040, n=5). However, despite co-culture, ROS was still able to be significantly induced
in all cases of patients (p=0.046, n=5) (Fig 24B).

Figure 24. Stromal co-culture increases GSH in CLL cells. A, CLL cells were seeded on
NKTert (CLL:NKTert, 20:1 ratio) for either 4 or 24hr and measured for total GSH
concentrations. B, CLL cells were treated with 1μM Auranofin for 1hr either alone or on
NKTert cells and assessed for ROS production by DCF-dA staining (n=5). Points represent
mean fluorescence intensity. Student’s t test was performed to determine p values.
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As there was a change in the intracellular antioxidant pool, we next sought to
determine if protein expression of Auranofin’s target, TxnR was observed. CLL cells were
seeded atop NKTert cells for 24 hr prior to collection. CLL cells appeared to have elevated
expression of TxnR1 upon co-culture when comparing A (alone) versus +N (with NKTert)
(Fig 25A). To ensure that the increase in TxnR1 was not due to artifact of NKTert cells, we
collected NKTert supernatant (CM) from cells seeded at the same density and cultured CLL
cells for 24 hr. Also, to determine if elevated TxnR1 can also occur in other stromal cells,
CLL cells were seeded on HK cells at the same ratio (40:1, CLL:HK) for 24hr. In all cases,
TxnR1 was elevated compared to the alone group (Fig 25B).

Figure 25. Stromal co-culture leads to increased expression of Thioredoxin
Reductase 1 in CLL cells. A, Protein extracts from CLL cells co-cultured on NKTert
stromal cells (+N) or alone (A) for 24hr were immunobloted for TxnR1 to measure
expression levels (n=4). B, TxnR1 expression of CLL cells cultured alone (A), on NKTert
(NK), with media from NKTert cells (CM) or on HK cells (HK). β-actin was used as an
internal loading control for both blots.
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It is unclear whether the direct interaction between the CLL and stromal cells is the
reason for the increased sensitivity to Auranofin. To determine if this was the case, we used
a transwell co-culture system where a 0.3μm porous membrane was used to separate the
stromal cells and CLL cells. Despite being separated by a membrane, CLL cells were still
more sensitized to Auranofin than when cultured alone; 21.4% and 32.1% viable cells
remaining, respectively. However direct contact appears to still be more effective in killing
the CLL cells (14.9% viable cells remaining) than alone or while separated by a membrane.
(Fig 26A). Nonetheless, there consistently was significantly greater apoptosis to apoptosis
even with transwell culture than alone when treated with 1μm Auranofin for 24hr (Fig 26B).
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Figure 26. Direct contact with stroma is not required for increased sensitivity to
Auranofin for CLL. A, CLL cells were treated with 1μM Auranofin alone, on NKTert, or with
NKTert but separated by 3μm membrane insert (transwell) for 24hr. Cells were assessed
for apoptosis by AnnexinV/PI assay. B, AnnexinV positivity of CLL cells treated with1μM
Auranofin alone or with NKTert transwell was determined after 24hr (p=0.0221, n=4).
Student’s t test was used to determine p value.

There are two major pathways for apoptosis: the intrinsic and extrinsic pathway. The
intrinsic path utilizes the mitochondria to activate a cascade of events for cell death. The
extrinsic pathway utilizes signals from receptors on the cell membrane to initiate cell
death119. CLL cells were treated with 1μM Auranofin for three and five hours before
collection. Probing for caspase-8, indicative of the extrinsic apoptosis pathway, was shown
to be activated as there was an increased in the 43kDa caspase-8 product while decrease
in the 57kDa band. Next, we probed for caspase-7, which is downstream and can be
cleaved and activated, by caspase-8. Similar to caspase-8, there was a time-dependent
decrease in the full length caspase-7 (FL Casp-7) at the 35kDa mark; whereas the cleaved
product accumulated at the 20kDa region (Fig 27).

Figure 27. Auranofin activates caspases in CLL. Protein extracts of a CLL patient
treated with 1μM Auranofin for 3 and 5hr were immunblotted for Caspase-8 and Caspase-7.
β-actin was used as a loading control.
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As Auranofin lead to significant ROS production in CLL cells and stromal co-culture
resulted in increased cell death, we sought to determine if this was due to a ROS based
mechanism. To test this, antioxidants: catalase (CAT) and sodium pyruvate (PYR) were
used in combination with Auranofin on CLL cells. CAT provided minimal protection against
Auranofin alone as significant AnnexinV positivity was measured with Auranofin alone (φ,
p<0.001) and in combination with CAT (φφ, P<0.0001) (Fig 28A). Similarly, significant
apoptosis was observed upon co-culture upon treatment with Auranofin alone (π, p<0.005)
and in combination with CAT (φφ, P<0.0001). In contrast to the alone group, CAT did afford
significant protection against Auranofin in NKTert co-cultured CLL cells (φφ, P<0.0001).
In contrast to CAT, PYR afforded no protection to Auranofin for CLL cells. Despite minimal
response to Auranofin for this patient in the ‘alone’ group, significant apoptosis was
observed upon NKTert co-culture (**, p<0.01) and no protection when PYR was added (φ,
p<0.001) (Fig 28B).
To see if this would consistently be the case, several more CLL patient samples
were tested. In total, four of five CLL patients showed decreased apoptosis in the NKTert
co-cultured group when 500U of CAT was used together with 1μM Auranofin (Fig 28C).
However, all five CLL patients in the ‘alone’ group did not see a decrease in apoptosis
despite the addition of CAT. Two CLL patients exhibited more cell death when combined
with CAT. There was only one such case in the NKTert co-cultured group where CAT+ AF
lead to greater apoptosis. For the other four patients, there was a trend in reduction in the
degree of apoptosis when CAT was added to Auranofin (Fig 28C).To further determine if
there was any selectivity in antioxidant protection, PYR and NAC was also tested in
combination with Auranofin. 3mM PYR itself did not affect the viability of the CLL cells and
had no significant protective effect when combined with 1μM Auranofin in either the alone
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or NKTert co-cultured group. In both cases, CLL cell viability was significantly decreased
with 1μM Auranofin alone (p<0.01) and when in combination with PYR (p<0.001) (Fig 28B)

76

77

Figure 28. Catalase protects Auranofin induced apoptosis on CLL cells co-cultured
on stromal cells. A, CLL cells were treated with 500U catalase (CAT), 1μM Auranofin
(AF), or in combination for 24hr either alone or on NKTert cells and assessed for Annexin
positivity. Both treatment lead to significant apoptosis relative to CAT control: 1μM AF, φ,
p<0.001, and AF+CAT, φφ, p<0.0001 in CLL cells alone and on NKTert: 1μM AF, π,
p<0.005, and AF+CAT, φφ, p<0.0001. AF+CAT relative to AF alone when co-cultured on
NKTert cells had significantly greater percentage of viable cells **, p=0.0010. B, CLL cells
were treated with 1mM sodium pyruvate (PYR), 1μM Auranofin (AF), or in combination for
24hr either alone or on NKTert cells and assessed for apoptosis. AF lead to significant
reduction in cell viability when co-cultured on NKTert, p =0.0010 while combination of AF +
PYR did not afford any protection for CLL cells φ, p<0.001. C, CLL cells were treated with
500U CAT, 1μM Auranofin (AF) or in combination (AF + CAT) either alone or on NKTert for
24hr and assessed for Annexin positivity. AF lead to significantly increased percentage of
AnnexinV+ cells relative to CAT, p = 0.0012 and p = 0.0011, either alone or with NKTert,
respectivly. Combination with AF+CAT did not lead to significant changes relative to AF
alone (n=5). Student’s t test was used to determine p-values. (φ, p<0.001, φφ, p<0.0001).

When CLL cells were treated with 2mM NAC in combination with 1μM Auranofin
and analyzed for apoptosis after 24h of treatment, the percentage of viable cells were
significantly increased compared to no NAC (p=0.0005, n=4). Likewise, CLL cells cocultured on NKTert cells were also protected when NAC was used (p<0.0001, n=4) (Fig
29A). The protection afforded by the addition of NAC may be either due to 1) NAC boosting
the intracellular GSH pool in the CLL or 2) neutralizing the activity of Auranofin through
binding of the sulfhydryl groups present in cysteine. In order to decipher which of these two
could be the case, an Auranofin neutralization assay was done. CAT, PYR, NAC and GSH
were each added to the medium followed by addition of Auranofin and incubated for one
hour. Following the incubation, CLL cells were directly added to the respective wells and
incubated for 24hr (Fig 29B). PYR and CAT had no neutralizing effect as CLL cells had
significant cell death in response to Auranofin as the control ‘alone’ group. In contrast, NAC
and GSH neutralized Auranofin by over 50% as there was an average 89 and 82% viability,
respectively in comparison to the Auranofin alone group (40% viable).
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Figure 29. Neutralization of Auranofin by antioxidants. A, CLL cells were treated with
1μM Auranofin or in combination with 2mM NAC either alone or while seeded atop NKTert
cells. Cells were treated for 24hr prior to assessing relative viability by AnnexinV/PI (n=4).
B, Auranofin was incubated either alone, with 1mM PYR, 500U CAT, 2mM NAC or 1mM
NAC for 1hr in culture medium prior to addition of CLL cells. Cells were incubated for 24hr
prior to assessing for cell death (n=2). Representative dot graph of results are shown
below. Student’s t test was used to determine p values.
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Auranofin falls into the category of gold-containing complexes and it is not known
whether this increase in sensitivity of CLL cells upon co-culture is due to the presence of
gold in the compound. Would the same response be seen if other metal containing
compounds were used? To determine this, Auranofin (Fig 30A), Chloro[diphenyl(otolyl)phosphine]gold(I) (CDPPE) (Fig 30B) and trans-diamminedichloroplatinum(II) (TPLN)
(Fig 30C) were compared. CDDPE also contains gold while TPLN, the trans form of the
chemotherapeutic agent cisplatin, contains platinum. CLL cells were treated with either 1μM
Auranofin, 1μM CDPPE or 10μM TPLN alone or on NKTert cells for 24hr and assessed for
apoptosis induction. This patient showed minimal apoptosis induction with 1μM Auranofin
alone but this was significantly increased to over 70% when co-cultured on NKTert
(p=0.003). Oppositely CLL cells were quite sensitive to CDPPE alone but this was
significantly diminished when cells were with NKTert (p<0.0001). TPLN showed minimal
activity alone and this was even more so diminished when treated on stromal cells
(p=0.0211) (Fig 31).
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Figure 30. Structure of metal containing drugs. A, Auranofin. B, Chloro[diphenyl(otolyl)phosphine]gold(I) (CDPPE). C, trans-diamminedichloroplatinum(II) (TPLN).

Figure 31. Apoptosis induction by metal containing drugs. CLL cells were treated with
1μM Auranofin, 1μM CDPPE or 10μM TPLN either alone or while co-cultured on NKTert
cells. Cells were treated for 24hr prior to assessing for cell death by AnnexinV/PI assay.
Student’s t test was used to determine p values.
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5.3 Discussion

The aim of this study was to determine whether altering the redox status in CLL
cells can be a therapeutic strategy to overcome drug resistance. We utilized Auranofin, an
FDA approved drug used to treat rheumatoid arthritis and known to inhibit TxnR188 .
Previous studies from our and other labs have shown the therapeutic potential of redox
altering drugs. Auranofin has been shown to be effective in inducing apoptosis in multiple
types of tumor types85, 89.
We determined that all CLL samples that underwent the MTT assay showed
sensitivity to Auranofin although there was a range in IC50 values for each of the patients. It
is possible that sensitivity towards Auranofin could be correlated to expression of TxnR1 as
there also were varying levels of TxnR1 expression (Figure 18B, C). However, an increased
sample pool would be required to determine whether there would be any positive
correlation between TxnR1 protein expression levels and sensitivity towards Auranofin.
We also determined CLL cells underwent apoptosis upon treatment with Auranofin,
but importantly, contrary to other studies where cells were more resistant to cytotoxic
agents such as fludarabine and oxaliplatin upon co-culture117, CLL cells were significantly
more sensitized to Auranofin (p<0.0001, n=23). This is a significant finding as overcoming
the protective effect of the microenvironment poses as a significant hurdle in not only CLL
but other hematological and non-hematological malignancies. That this phenomenon was
observed with not only one type of stromal cell line but also with HK lymph node stromal
cells (p=0.0139, n=4) suggests that this response may also be possible in in vivo as well. In
addition, no cell death was observed when stromal cells were assessed for cell death with
Auranofin treatment. These results were encouraging as selective toxicity towards
tumorigenic cells is always at the forefront of searching for a new therapeutic agent.
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Intriguingly, we found that direct contact with the stromal cells is not required for the
increased sensitivity towards Auranofin. We used a transwell insert to separate CLL cells
from NKTert stromal cells. As a representative experiment depicted, direct contact leads to
the most death (14.9% viable cells remaining) in response to Auranofin. However, there
was still significant death in the transwell group compared to alone, 21.4% and 32.1%
viable cells, respectively. We consistently observed this pattern upon testing further CLL
patient samples (p=0.0221, n=4). These results hinted us towards two possibilities: 1) that
Auranofin is leading to increased secretion of a product which is damaging to CLL cells or
2) Auranofin is inhibiting the release of cytoprotective molecules (i.e IL-6).
Auranofin falls into the category of gold(I) phosphine containing complexes and their
analogs have been evaluated for anti-tumor activity85, 87, 88, 93. We wanted to determine if the
increased activity or Auranofin towards CLL co-culture was due to the gold contained within
the structure, or it if was the overall chemical itself. It was important to answer this question,
as, if it was a metal-based mechanism for the increased activity, perhaps another metal containing agent would be just as efficacious. To determine if this was the case, we
obtained two other metal-containing agents: Chloro[diphenyl(o-tolyl)phosphine]gold(I)
(CDPPE) and trans-diamminedichloroplatinum(II) (TPLN). CDPPE is analogous to
Auranofin as it is a gold(I) containing phosphine complex while TPLN contains the metal
platinum. The results from this study determined that it is because of Auranofin itself that
there is an increase in sensitivity upon stromal co-culture. Despite CDPPE being
significantly cytotoxic to CLL cells alone, there was diminished cell death upon co-culture.
TPLN was even less cytotoxic to CLL cells both alone and in co-culture. We can conclude
with these results that it is not the gold/metal itself that matters, but the overall structure of
Auranofin which exerts the unique response that is observed.
In order to determine the mechanism by which CLL cells are more responsive to
Auranofin, we sought to determine the redox alterations which occur upon treatment. We
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observed a dose dependent increase in ROS production in CLL cells within an hour of
treatment; but this elevation was diminished by 2hr of treatment. Despite this relatively short
oxidative burst, we hypothesized that Auranofin may trigger extracellular release of ROS by
the stromal cells. To test this, we treated cells with CAT, as this can readily quench H2O2 in
the extracellular medium but is too large to enter into the cell. CAT significantly increased
the viability of CLL cells that were co-cultured on stromal cells in 3 out of 4 cases but this
was achieved for only one patient in the ‘alone’ group. Although this cannot completely
explain the increased cell death, we can infer from the protective effect observed in the cocultured group that extracellular ROS release by the stromal cells does have a part in the
increased apoptosis.
Elevated antioxidants have been observed in cancer cells relative to their normal
counterparts. Furthermore, genetic aberrations such as oncogenic mutations (KRAS) can
lead to altered ROS production and thus result in an altered tolerance to oxidative stress61.
We wanted to test if antioxidants could protect CLL cells against Auranofin. NAC was able
to better protect both the ‘alone’ and co-cultured group in all cases; even more so than
CAT. The least effective antioxidant was PYR with no protective effect in either the alone or
co-cultured groups. Looking at the mechanisms of protection by each of the antioxidants,
we can speculate as to how Auranofin can be more cytotoxic to CLL cells in the co-cultured
condition. NAC could have prevented Auranofin-induced cell death by several mechanisms.
First, NAC can function as an antioxidant itself and eliminate ROS. Second, NAC is a
precursor to GSH and studies have shown supplementing cells with NAC can restore GSH
levels. Thus, NAC could have prevented cell death by restoring the GSH that was depleted
by Auranofin. Third, although not a mechanism by design, NAC itself may have neutralized
Auranofin as it contains sulfyhdryls that are open to conjugation by Auranofin.
Pharmacological studies of Auranofin showed it can bind to serum albumin as well as to the
sulfhydryls within TxnR15.
84

In order to decipher which of these case(s) could be the protective effect by NAC,
we performed an Auranofin neutralization assay. Pre-incubating Auranofin with CAT, PYR,
NAC or GSH for an hour prior to addition of CLL cells showed whether it was Auranofin
conjugating to the antioxidant or not. Auranofin was nearly completely neutralized with NAC
and GSH; both cysteine and therefore, sulfhydryl containing antioxidants. CAT and PYR on
the other hand, had no protective effect against Auranofin on CLL cells. These results are
important as future combination studies with Auranofin need to be carefully planned. In
addition, as Auranofin is administered orally, patients taking other oral supplements such as
NAC and GSH may neutralize the effectiveness of the drug.
Previous studies in our lab have shown that stromal cells provide protection of CLL
cells by modifying its redox environment117. Indeed, as previously shown, stromal co-culture
was able to elevate total GSH levels with the CLL cells. It is also well known that GSH
depletion can be deadly to cells62, 63. We sought to determine what redox alterations occur
upon Auranofin treatment in CLL. We observed Auranofin significantly depleted GSH in
after 3hr (p=0.031,n=4) and 5hr (p=0.0078, n=4). This suggests that GSH depletion, in
addition to the extracellular ROS released by stromal cells can overwhelm the CLL cells;
thus, leading to increased cell death. To compound matters, we observed that Auranofin
altered the NADPH/NADP+ ratios in CLL cells after one hour of treatment. This result was
expected as TxnR1 utilizes NAPDH to obtain electrons to reduce oxidized TRX and thus,
inhibition of TxnR1 will lead to accumulation of NADPH.
A novel finding of this study was that CLL cells were more sensitive to Auranofin
whether in direct contact with the stromal cells or not. In addition, TxnR1 expression was
elevated in CLL cells upon direct contact with NKTert or HK cells, or with the conditioned
medium of NKTert cells. That TxnR1 expression levels increased despite lack of direct
contact may imply that it may be through release of a cytokine which triggered increased
expression of TxnR1. It is possible that the co-culturing, which lead to increased TxnR1, is
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the cause for the greater cytotoxicity observed to Auranofin. As TxnR1 is targeted by
Auranofin, increasing the target in CLL, whether it is initially triggered as a pro-survival
response, may be the mechanism for this increased cell death.
5.4 Future Directions

To further determine the mechanism of increased sensitivity of CLL cells to
Auranofin upon stromal co-culture, the following experiments are proposed:
As TxnR1 expression was elevated in CLL cells upon stromal co-culture and
because TxnR1 is Auranofin's target, if one were to have TxnR1 knockout cells (TxnR1-/-)
one could compare the sensitivity to Auranofin relative to the wild-type (TxnR1+/+). Cells
with TxnR1-/- would expected to be less sensitive towards Auranofin than TxnR1+/+ cells.
Further, all CLL cells that were immunoblotted for TxnR1 showed basal expression of the
protein. Transient siRNA knockdown of TxnR1 may be performed on CLL cells and
assessed for viability. It would be important to determine if the redox alterations observed
with Auranofin would also be seen with specific knockdown of TxnR1. In a reverse
experiment, full length cDNA ORFs of TxnR1 can be used for overexpression in CLL cells.
For this case, one woud anticipate that rather than a decrease in sensitivity, increased
cytotoxicity towards Auranofin would be observed. These experiments would help
determine whether the response to Auranofin is due to the level of TxnR1 present.
Auranofin has been shown to reduce inflammation in patients with rheumatoid
arthritis. Production of inflammatory cytokines: TNF-alpha, interleukin-beta, and interleukin6 by macrophages were reduced when treated with Auranofin120, 121. As stromal cells are
known to secrete cytokines which mediate survival signals, it is possible that Auranofin is
inhibiting cytokine release and in turn secreting death-initiating signals. TxnR1 expression
increased in CLL without direct stromal contact, as adding CLL cells to media collected
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from NKTert cells was able to show. Further, the increased sensitivity towards Auranofin
was replicated, although to a lesser extent, even when CLL and stromal cells were
separated by a PVDF membrane insert. Auranofin may be inhibiting the release of prosurvival signals for CLL such as interleukin-6, while triggering aggregation of death domaincontaining receptors. An ELISA of the following conditions: CLL alone, with and without
Auranofin and CLL + stromal cells with and without Auranofin may give insight to changes
in the microenvironment.
Lastly, further in vivo studies to understand how Auranofin reduced the tumor
burden and extended the survival of TCL1/p53-/- is needed. The study by Fiskus et al.
showed a two-week treatment of 5 days/week of Auranofin significantly reduced leukemia
burden while increasing survival time93. However, the exact mechanism to the reduction of
leukemic cell burden is yet unknown. It would be important to extend this study in not only
TCL1/p53-/- mice, but also in TCL1/p53+/+ and TCL1/p53+/- groups as survival times
significantly differ with wildtype and heterozygous p53. Following Auranofin treatment, a
complete examination of organs, particularly histology of spleens and lymph nodes should
be performed. In addition, examination of other lymphoid cell types, to see whether any
changes in cell number, or secretion of cytokines, are occurring in these cells could be
important in understanding how leukemia cell burden is being reduced.
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Chapter 6
Overall Discussion and Conclusions

Several new findings in CLL biology were made during this study. First, further
characterization of the TCL1/p53−/− mice model was conducted. As there was only one
published study of this mouse model during the time of this study, the biology of the
mitochondria in these mice were yet unknown. Previous studies in p53 knockout mice have
shown decrease in mitochondria biogenesis, while cell lines showed impaired mitochondria
respiratory capacity upon loss of p53. Rather than seeing diminished mitochondria function
and decrease in mitochondrial biogenesis, we observed a compensatory response in the
mice. This is supported by the increased expression of TFAM and PGC1α. Furthermore,
del17p CLL patients also had increased protein expression of both these transcriptional
regulators. These results support the notion that upon loss of p53, leukemic cells induce a
positive feedback signal to maintain, as much as possible, normal mitochondria function.
The second interesting finding of this study was the elevated expression of EZH2 in
TCL1/p53−/− mice; although this pattern was not observed in del17p patients. The
dichotomy of these observations may be due to biological differences between the CLL
mouse and human models. It is also possible that other abnormalities found in CLL patients
can trump the repressive activities of p53 on EZH2. Despite EZH2 expression differences,
use of two EZH2 inhibitors, DZNep and GSK126 on CLL patients resulted in a response
contrary to what has been reported in the literature. Rather than inhibition of H3K27(Me)3,
maintenance and elevation of trimethylation was observed. It would be worth looking at
whether EZH1 is compensating for EZH2 upon treatment with GSK126. However, as the
increased trimethylation was also observed with the less specific EZH2 inhibitor, DZNep,
EZH1 compensation may not be the cause. This study was not able to identify the
mechanisms to this increase in methyltransferase activity, but, future studies should look at
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whether there are EZH2 mutations in CLL. Based on the findings of this study, EZH2
inhibitors may not be an ideal therapeutic strategy for CLL.
Lastly, we sought to determine if Auranofin would have any therapeutic efficacy in
CLL. Auranofin indeed triggered apoptosis in CLL cells and importantly, upon co-culture
with stromal cells, were consistently more sensitive to the drug. Numerous studies support
the CLL microenvironment in maintaining CLL viability and protection against DNA
damaging agents. That Auranofin can overcome this protective effect in CLL patients
despite having prior therapy, makes it an intriguing agent. Further, TxnR1 expression was
elevated in CLL cells upon stromal co-culture or incubation with stromal cell conditioned
medium. As TxnR is a target of Auranofin, this increase in TxnR1 expression could be the
reason for the elevated cytotoxicity. ROS production and GSH depletion were additional
alterations that likely contributed to induction of apoptosis by Auranofin. However, the
mechanism by which stromal co-culture increases the sensitivity of CLL cells towards
Auranofin is yet unknown; and future experiments to decipher the mechanisms are
proposed. The minimal cytotoxicity of Auranofin towards the stromal cells and that it is
currently an FDA approved agent warrants further investigation as a therapeutic option in
CLL.
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